

CURRICULUM VITAE

Milton Packer, M.D.

Office Address: Baylor University Medical Center
Baylor Heart and Vascular Hospital
621 N. Hall Street
Dallas, Texas 75226

EDUCATION

- 1964-1968 Central High School, Philadelphia, Pennsylvania
B.A. degree (honorary), valedictorian.
- 1968-1969 Pennsylvania State University, State College, Pennsylvania
B.S. degree (1971) with highest distinction.
- 1969-1973 Jefferson Medical College, Philadelphia, Pennsylvania
M.D. degree (1973), summa cum laude, first in class.
- 1973-1974 Intern, Internal Medicine, Bronx Municipal Hospital Center,
Albert Einstein College of Medicine, Bronx, New York.
- 1974-1975 Junior Resident, Internal Medicine, Bronx Municipal Hospital
Center, Albert Einstein College of Medicine, Bronx, New York.
- 1975-1976 Senior Resident, Internal Medicine, Bronx Municipal Hospital
Center, Albert Einstein College of Medicine, Bronx, New York.
- 1976-1977 Fellow in Cardiology, Mount Sinai School of Medicine,
New York, New York
- 1977-1978 Kriendler-Berns Foundation Fellow in Cardiology, Mount Sinai
School of Medicine, New York, New York

Milton Packer, M.D.

ACADEMIC APPOINTMENTS

- 1978-1979 Instructor in Medicine (Cardiology and Clinical Pharmacology),
Mount Sinai School of Medicine, New York, NY
- 1979-1983 Assistant Professor of Medicine (Cardiology and Clinical
Pharmacology), Mount Sinai School of Medicine, New York, NY
- 1983-1988 Associate Professor of Medicine (Cardiology and Clinical
Pharmacology), Mount Sinai School of Medicine, New York, NY
- 1988-1992 Professor of Medicine (Cardiology), Mount Sinai School of Medicine,
New York, NY
- 1992-2004 Dickinson W. Richards Jr. Professor of Medicine and of Pharmacology
(with tenure), Columbia University College of Physicians & Surgeons,
New York, NY
- 2004-2015 The Gayle and Paul Stoffel Distinguished Chair in Cardiology
Professor of Clinical Sciences (with tenure), University of Texas
Southwestern Medical School, Dallas, TX
- 2015- Distinguished Scholar in Cardiovascular Science, Baylor University
Medical Center, Dallas, TX
- 2018- Visiting Professor, Faculty of Medicine, National Heart and Lung
Institute, Imperial College, London, UK

Milton Packer, M.D.

HOSPITAL APPOINTMENTS

- 1978-1983 Assistant Attending Physician, The Mount Sinai Hospital, New York, NY and the Bronx Veterans' Administration Hospital, Bronx, NY
- 1983-1988 Associate Attending Physician, The Mount Sinai Hospital, New York, NY and the Bronx Veterans' Administration Hospital, Bronx, NY
- 1988-1992 Attending Physician, The Mount Sinai Hospital, New York, NY and the Bronx Veterans' Administration Hospital, Bronx, NY
- 1992-2004 Attending Physician, Presbyterian Hospital, Columbia-Presbyterian Medical Center, New York, NY

ADMINISTRATIVE APPOINTMENTS

- 1978-1988 Director, Ames and Rose Coronary Care Units, The Mount Sinai Medical Center, New York, NY
- 1983-1992 Director, Cardiovascular Training Program, The Mount Sinai Medical Center, New York, NY
- 1992-2004 Chief, Division of Circulatory Physiology and Director, Heart Failure Center, Columbia-Presbyterian Medical Center, New York, NY
- 2004-2006 Director, Center for Biostatistics and Clinical Sciences University of Texas Southwestern Medical School, Dallas, TX
- 2007-2012 Principal Investigator, NIH Clinical and Translational Science Award, University of Texas Southwestern Medical School, Dallas, TX
- 2006-2015 Chair, Department of Clinical Sciences University of Texas Southwestern Medical School, Dallas, TX

BOARD CERTIFICATIONS

- Diplomate, National Board of Medical Examiners, 1975
- Diplomate, American Board of Internal Medicine, 1976
- Diplomate, American Board of Internal Medicine, Subspecialty in Cardiovascular Diseases, 1979

Milton Packer, M.D.

AWARDS AND HONORS

Medical School

Eben J. Carey Memorial Award in Anatomy, Jefferson Medical College, 1970
Francis W. Shain Physiology Prize, Jefferson Medical College, 1970
Lange Medical Publications Prize, Jefferson Medical College, 1970
Melvin I. Katzman Pathology Prize, Jefferson Medical College, 1971
Alpha Omega Alpha, (vice-president), Jefferson Medical College, 1972
Edmund J. Laurelli Obstetrics and Gynecology Prize, Jefferson, 1972
Lange Medical Publications Prize, Jefferson Medical College, 1972
Hobart Amory Hare Honor Society, Jefferson Medical College, 1972
Henry Keller Mohler Memorial Prize for Therapeutics, Jefferson, 1972
Henry M. Phillips Prize for Surgery, Jefferson Medical College, 1973
William Potter Memorial Prize, Jefferson Medical College, 1973
The Alumni Scholastic Medal, Jefferson Medical College, 1973

Postgraduate Awards

Solomon A. Berson Award for Excellence in House Staff Teaching,
Department of Medicine, Mount Sinai School of Medicine, 1983

Research Career Development Award, National Heart, Blood and Lung Institute,
The National Institutes of Health, 1984-1989

Simon Dack Award for Excellence in Teaching of Cardiovascular Medicine,
Division of Cardiology, Mount Sinai School of Medicine, 1988

Irving Clinical Research Scholar, Columbia University,
College of Physicians and Surgeons, New York, New York, 1992-1995

Henry Christian Award for Excellence in Clinical Research, American Federation
for Clinical Research, Washington, D.C., 1993

Chancellor's Health Fellow in Research, University of Texas
Board of Regents, 2006

Lewis Katz Lifetime Achievement Award in Cardiovascular Research,
Columbia University College of Physicians and Surgeons, 2010

Milton Packer, M.D.

AWARDS AND HONORS

Named Lectureships and Visiting Professorships

- David Scherf Memorial Lectureship, New York Medical College,
Lenox Hill Hospital, New York, New York, May 3, 1985
- John Hammond Memorial Lecture, St. Louis University,
St. John's Mercy Medical Center, St. Louis, Missouri, November 26, 1985
- Amon G. Carter Visiting Professorship, Southwestern Medical School,
University of Texas Health Sciences Center at Dallas, May 26-27, 1988
- Edward W. Dennis, M.D. Memorial Lecturer, Baylor Medical School,
Ben Taub Hospital, Houston, Texas, June 8, 1989
- The Royal RHL Lecture, Swedish Society of Cardiology,
Stockholm, Sweden, November 27, 1989
- Osler Award for Excellence in Cardiovascular Teaching,
University of Miami School of Medicine, May 25, 1991
- Ira Pores Memorial Lecture in Cardiology, Beth Israel Hospital
Newark, New Jersey, May 30, 1991
- Understien Memorial Lecture, George Washington University,
Washington, D.C., May 13, 1992
- Carl J. Wiggers Memorial Lecture, Cleveland American Heart
Association Affiliate, Cleveland, Ohio, March 4, 1993
- Donald Zucker Visiting Professor, Cornell University Medical Center,
New York, New York, April 14, 1994
- Helen M. Dalsheimer Lectureship, Sinai Hospital (Johns Hopkins),
Baltimore, Maryland, May 19, 1994
- Kenneth Rosen Visting Professor, University of Illinois,
Chicago, Illinois, December 1, 1994
- Newton H. Stern Visting Professor, University of Tennessee,
Memphis, Tennessee, May 26, 1994
- Louis F. Bishop Lectureship, American College of Cardiology,
New Orleans, Louisiana, March 22, 1995
- O. J. Tauber Lectureship, Texas Heart Institute,
Houston, Texas, September 6, 1995
- State-of-the-Art Lecturer, Canadian Cardiovascular Society,
Toronto, Canada, October 25, 1995
- James Alexander Visiting Professor, Baylor University,
Houston, Texas, June 24-25, 1996

Milton Packer, M.D.

AWARDS AND HONORS

Named Lectureships and Visiting Professorships (continued)

- First New York Cardiac Center Lecturer, New York Cardiological Society, New York, New York, February 11, 1997
- Visiting Professor and State-of-the-Art Lecturer, University of Rochester, Rochester, New York, April 17, 1997
- Visiting Professor and State-of-the-Art Lecturer, Yale University, New Haven, Connecticut, April 23, 1998
- Visiting Professor and State-of-the-Art Lecturer, St. Louis University, St. Louis, Missouri, May 31, 2002
- Visiting Professor and State-of-the-Art Lecturer, University of Texas Health Sciences Center, Houston, Texas, April 24, 2003
- Visiting Professor and State-of-the-Art Lecturer, Johns Hopkins University, Baltimore, Maryland, November 11, 2003
- Louis Katz Visiting Professor and Lecturer, Columbia University College of Physicians & Surgeons, New York, New York, November 4, 2010
- Louis Katz Visiting Professor and Lecturer, Columbia University College of Physicians & Surgeons, New York, New York, November 4, 2010
- Heller Visiting Professor and State-of-the-Art Lecture, New York University, New York, New York, April 20, 2012
- Visiting Professor and State-of-the-Art Lecture, Northwestern University, Chicago, Illinois, February 29, 2016
- Visiting Professor and Lecturer, Cleveland Clinic, Lerner College of Medicine, Cleveland, Ohio, June 6, 2016
- Arnold Johnson Visiting Professor, McMaster University, Hamilton, Canada, November 21-23, 2016
- Philip Poole-Wilson Lecture, Royal Brompton Hospital, Imperial College, United Kingdom, December 15, 2017
- Keynote Lecturer, University of Utah Cardiac Recovery Symposium, Salt Lake City, January 11, 2018
- Hatter Award Lecture, Royal College of Physicians, London, United Kingdom, April 8, 2019
- Paul Wood Lecture and Visiting Professor, British Cardiovascular Society, Manchester, United Kingdom, June 3, 2019
- Viscount St. Cyres Lecture, Governance Day, Royal Brompton Hospital, London, United Kingdom, June 3, 2019
- Hans Hecht Visiting Professor, Division of Cardiology, University of Chicago Medical School, Chicago, October 5-6, 2019

Milton Packer, M.D.

LICENSURE

New York

Texas

SOCIETIES

Alpha Omega Alpha

Member, American Federation for Clinical Research

Fellow, American College of Cardiology

Member, Council on Clinical Cardiology, American Heart Association

Member, Association of University Cardiologists

Elected, American Society for Clinical Investigation

President, Heart Failure Society of America (2000-2002)

Fellow, Heart Failure Society of America

EDITORSHIPS

Global Advisory Editor, Circulation (2016-present)

International Editorial Board, European Heart Journal (2018-present)

MEDICAL PUBLISHING (DIGITAL)

Milton Packer, Revolution and Revelation, MedPage Today (2017-present)

Recipient, Jesse H. Neal Award, Best Commentary/Blog, 2018

ASBPE Awards of Excellence, Bronze Regional Award,
Blog-Analysis/Commentary, 2018

Milton Packer, M.D.

STUDY SECTIONS

Study Section, Specialized Centers of Research, Cardiology Branch,
National Heart, Lung and Blood Institute, Cardiology Branch, 1989-1990

Study Section for Medical Student Clinical Research, Howard Hughes Medical
Institute, 2006-2009

NATIONAL INSTITUTES OF HEALTH (NIH) COMMITTEES

Task Force on Heart Failure Research, Clinical Trials Branch,
National Institutes of Health, 1983

Chairman, Review Committee, National Heart Failure Intervention Trial,
Studies of Left Ventricular Dysfunction (SOLVD), Clinical Trials Branch,
National Institutes of Health, 1985

Data and Safety Monitoring Board, National Heart Failure Intervention Trial,
Studies of Left Ventricular Dysfunction (SOLVD), Clinical Trials Branch,
National Institutes of Health, 1985-1991

Protocol Review Committee, Clinical Evaluation of the Implantable Novacor
Left Ventricular Assist System, NHLBI, 1991-1992

Chair, Data and Safety Monitoring Board, Sudden Cardiac
Death in Heart Failure (SCD-HeFT), NHLBI, 1998-2002

Chair, Operations Committee, Evaluation of Mechanical Assistance
in Heart Failure (REMATCH, 1997-2002)

Milton Packer, M.D.

RESEARCH GRANTS (PEER-REVIEW)

NATIONAL INSTITUTES OF HEALTH

Principal Investigator

Young Investigator's Award, National Institutes of Health,
(1 R23 HL-25055), 1980-1983

Research Grant, Determinants of Vasodilator Response in Heart Failure,
National Institutes of Health, (1 R01 HL-25055), 1983-1988

Research Career Development Award, National Institutes of Health,
(1 K04 HL-01229), 1984-1989

Research Grant, Determinants of Vasodilator Response in Heart Failure,
National Institutes of Health, (2 R01 HL-25055), 1988-1993

Multidisciplinary Clinical Research Career Development Award, National
Institutes of Health (trans-NIH K12), 2005-2010

Clinical and Translational Science Award (CTSA), National Institutes of
Health, 2007-2012

Co-Investigator

Cardiovascular Research Training Grant, T32 HL-07347,
National Institutes of Health, 1983-1988

General Clinical Research Center Grant, M01 RR-00071,
National Institutes of Health, 1991-1995; 1996-2001

Co-Investigator and Director of Operations, Randomized Evaluation of
Mechanical Assistance in Heart Failure (REMATCH), 1997-2002

Co-Investigator and PI of Core 5, UT Southwestern Population-based Research
Optimizing Screening through Personalized Regimens (PROSPR)
(U54). 2013-2015

Milton Packer, M.D.

NATIONAL MULTICENTER TRIAL STEERING COMMITTEES

Executive Committee, Vasodilator Therapy Post-Myocardial Infarction, Survival and Ventricular Enlargement (SAVE), 1986-1992

Chairman, Mortality/Endpoint Committee, Vasodilator Therapy Post-Myocardial Infarction, Survival and Ventricular Enlargement (SAVE), 1986-1992

Principal Investigator and Chair, Steering Committee, Multicenter Study of the Effect of Flosequinan in Heart Failure (REFLECT), 1987-1989

Principal Investigator and Chair, Steering Committee, Multicenter Study of the Effect of Amlodipine in Heart Failure, 1987-1989

Principal Investigator and Chair, Steering Committee, Prospective Randomized Milrinone Survival Evaluation (PROMISE), 1988-1990

Chair, Steering Committee, Multicenter Study of Digoxin in Heart Failure Treated with Converting-Enzyme Inhibitors (RADIANCE), 1989-1992

Member, Data and Safety Monitoring Board, Arrhythmia Heart Failure Survival Trial, Veterans Administration (CSP 320), 1989-1993

Principal Investigator and Chair, Executive Committee, Prospective Randomized Flosequinan Longevity Evaluation (PROFILE), 1991-1994

Principal Investigator and Chair, Steering Committee, Effect of Amlodipine on Morbidity and Mortality in Heart Failure (PRAISE), 1992-1995

Principal Investigator and Chair, Steering Committee, Assessment of Treatment with Lisinopril on Survival in Heart Failure (ATLAS), 1993-1997

Principal Investigator and Chair, Steering Committee, Multicenter Study of Effect of Carvedilol in Heart Failure (PRECISE), 1993-1995

Principal Investigator and Chair, Steering Committee, Effect of Amlodipine Mortality in Heart Failure (PRAISE 2), 1996-1999

Principal Investigator and Chair, Steering Committee, Effect of Carvedilol on Mortality in Heart Failure (COPERNICUS), 1997-2002

Member, Data and Safety Monitoring Board, Comparison of Carvedilol and Metoprolol on Survival in Heart Failure (COMET), 1996-1998

Member, Data and Safety Monitoring Board, Effect of Angiotensin II Receptor Blockade and Beta-Blockade in Heart Failure (RESOLVD), 1996-1999

Principal Investigator and Chair, Steering Committee, Effect of Bosentan on Clinical Status in Heart Failure (REACH-1), 1997-2003

Milton Packer, M.D.

NATIONAL MULTICENTER TRIAL STEERING COMMITTEES (CONTINUED)

Member, Steering Committee, VA Study on the Effect of Anticoagulation on Clinical Events in Heart Failure (WATCH), 1997-1999

Principal Investigator and Chair, Steering Committee, Effect of Bosentan on Morbidity and Mortality in Heart Failure (ENABLE), 1999-2001

Principal Investigator and Chair, Steering Committee, Effect of Omapatrilat on Morbidity and Mortality in Heart Failure (OVERTURE), 1999-2002

Chair, Steering Committee, Effect of Etanercept on Morbidity and Mortality in Heart Failure (RENEWAL), 1999-2002

Principal Investigator and Chair, Steering Committee, Effect of Levosimendan in Patients with Decompensated Heart Failure (REVIVE I and II), 2001-2006

Member, Steering Committee, Effect of Spironolactone in Patients with Heart Failure and Preserved Systolic Function (TOPCAT), 2006-2013

Co-Principal Investigator and Co-Chair, Executive Committee, Effect of LCZ69 in Chronic Heart Failure (Reduced Ejection Fraction) (PARADIGM-HF), 2009-2014

Member, Steering Committee,, Effect of LCZ696 in Chronic Heart Failure (Preserved Ejection Fraction) (PARAGON-HF), 2013-2019

Principal Investigator and Chair, Executive Committee, Effect of Ularitide in Acutely Decompensated Heart Failure (TRUE-AHF), 2013-2017

Principal Investigator and Chair, Executive Steering Committee, Effect of Empagliflozin in Heart Failure with a Reduced Ejection Fraction (EMPEROR-Reduced), 2016-

Principal Investigator and Chair, Executive Steering Committee, Effect of Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved), 2016-

SOCIETIES

Heart Failure Society of America

Founding Member, 1996

Member, Executive Committee, 1996-2004

Secretary, 1996-1998

Vice-President, 1998-2000

President, 2000-2002

British Cardiovascular Society, Honorary Member, 2019-

Milton Packer, M.D.

FOOD AND DRUG ADMINISTRATION

Member, Cardiac and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 1986-1992

Consultant, Division of Cardiac and Renal Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 1987-1995

Chair, Cardiac and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 1997-2001

Consultant, Division of Cardiac and Renal Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 2001-present

Member, Cardiac and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 2016-

PUBLIC POLICY TASK FORCES

Consultant, RAND/AHCPR Guideline on Heart Failure: Outpatient Management of Patients with Left Ventricular Systolic Dysfunction

Task Force on Development of New Research Directions in Heart Failure, National Institutes of Health, NHLBI, 1998 and 2016

AMERICAN HEART ASSOCIATION/ AMERICAN COLLEGE OF CARDIOLOGY

Chair (1990-1993) and Vice-Chairman (1987-1990), Postgraduate Education Committee, Council on Clinical Cardiology, American Heart Association, 1987-1993

Program Committee, Council on Clinical Cardiology, 1988-1991

Executive Committee, ACC Scientific Sessions, 1990-1994

ACC/AHA Joint Committee on Cardiovascular Drugs, 1991-1994

Nominating Committee, Council on Clinical Cardiology, AHA 1991-1994

Member, Task Force on the Management of Heart Failure, ACC/AHA Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures, 1992-1995

Member, ACC/AHA Committee to Revise the 1995 Heart Failure Guidelines, 1999-2001

HEALTH CARE FINANCE ADMINISTRATION

Consultant on Heart Failure Programs, 1999-2001

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED) OF 465 PAPERS

1. Packer M, Meller J, Gorlin R, Herman MV. Clinical and hemodynamic tachyphylaxis to prazosin mediated afterload reduction in severe congestive heart failure. *Circulation* 1979; 59: 531-539.
2. Wiener I, Meller J, Packer M, Herman MV, Teichholz LE. Prognostic value of septal function in acute anteroseptal myocardial infarction — an echocardiographic study. *Am Heart J* 1979; 47: 726-732.
3. Packer M, Meller J, Gorlin R, Herman MV. Differences in the hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure. Evidence for a direct negative chronotropic effect of prazosin. *Am J Cardiol* 1979; 44: 310-317.
4. Packer M, Meller J, Medina N, Gorlin R, Herman MV. Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. *N Engl J Med* 1979; 301: 1193-1197.
5. Packer M, Meller J, Medina N, Gorlin R, Herman MV. Hemodynamic evaluation of hydralazine dosage in refractory heart failure. *Clin Pharmacol Ther* 1980; 27: 337-346.
6. Packer M, Meller J, Medina N, Gorlin R, Herman MV. Dose requirements of hydralazine in patients with severe chronic congestive heart failure. *Am J Cardiol* 1980; 45: 655-659.
7. Packer M, Meller J, Medina N, Gorlin R, Herman MV. Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. *N Engl J Med* 1980; 303: 250-255.
8. Urquhart J, Patterson RE, Packer M, Goldsmith SJ, Horowitz SF, Gorlin R. Quantification of valvular regurgitation before and after valve replacement surgery. *Am J Cardiol* 1981; 47: 287-291.
9. Wiener I, Kunkes S, Rubin D, Kupersmith J, Packer M, Pitchon R, Schweitzer P. Effect of sudden changes in cycle length on human atrial, AV nodal, and ventricular refractory periods. *Circulation* 1981; 64: 245-248.
10. Packer M, Meller J, Medina N, Yushak M, Gorlin R. Determinants of drug response in severe chronic heart failure. I. Activation of vasoconstrictor forces during vasodilator therapy. *Circulation* 1981; 64: 506-514.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

11. Packer M, Meller J, Medina N, Yushak M. Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs. *Am J Cardiol* 1981; 48: 375-379.
12. Packer M, Meller J, Medina N, Yushak M, Gorlin R. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. *Am J Cardiol* 1981; 48: 939-946.
13. Packer M, Meller J, Medina N, Yushak M, Gorlin R. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. *N Engl J Med* 1982; 306: 57-62.
14. Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG Jr, Gorlin R. Hemodynamic consequences of combined beta adrenergic and slow channel blockade in man. *Circulation* 1982; 65: 660-668.
15. Packer M, Greenberg B, Massie B, Dash H. Deleterious effects of hydralazine in patients with pulmonary hypertension. *N Engl J Med* 1982; 306: 1326-1331.
16. Packer M, Gorlin R, Medina N, Meller J. Central hemodynamic effects of intravenous and oral dipyridamole in patients with severe heart failure: preliminary evaluation and comparison with hydralazine. *Clin Pharmacol Ther* 1982; 32: 54-61.
17. Frishman W, Kirsten E, Klein M, Pine M, Johnson SM, Hillis LD, Packer M, Kates R. Clinical relevance of verapamil plasma levels in patients with stable angina pectoris. *Am J Cardiol* 1982; 50: 1180-1184.
18. Scheidt S, Frishman WH, Packer M, Mehta J, Parodi O, Bala Subramanian V. Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. *Am J Cardiol* 1982; 50: 1185-1190.
19. Packer M, Meller J, Medina N, Yushak M, Gorlin R. Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure. *Am J Cardiol* 1983; 51: 183-188.
20. Massie BM, Packer M, Hanlon JT, Coombs DT. Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. *J Am Coll Cardiol* 1983; 2: 338-344.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

21. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. *Circulation* 1983; 68: 803-812.
22. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe heart failure: Relation to activation of the renin angiotensin system and hyponatremia. *N Engl J Med* 1984; 310: 347-352.
23. Goldman ME, Packer M, Horowitz SF, Meller J, Patterson RE, Kukin M, Gorlin R. Relationship between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation. *J Am Coll Cardiol* 1984; 3: 924-929.
24. Packer M, Medina N, Yushak M. Relationship between serum sodium concentration and the hemodynamic and clinical responses to converting-enzyme inhibition with captopril in severe heart failure. *J Am Coll Cardiol* 1984; 3: 1035-1043.
25. Packer M, Medina M, Yushak M. Correction of dilutional hyponatremia in patients with severe chronic heart failure by converting-enzyme inhibition. *Ann Intern Med* 1984; 100: 782-789.
26. Packer M, Medina N, Yushak M, Wiener I. Detrimental effects of verapamil in patients with primary pulmonary hypertension. *Br Heart J* 1984; 52: 106-111.
27. Packer M, Medina M, Yushak M. Efficacy of captopril in low-renin congestive heart failure. Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. *Am J Cardiol* 1984; 54: 771-777.
28. Packer M, Medina N, Medina M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. *J Am Coll Cardiol* 1984; 4: 890-901.
29. Packer M, Medina N, Yushak M. Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. *Am J Cardiol* 1984; 54: 1025-1029.
30. Packer M, Medina N, Yushak M. Hemodynamic and clinical limitations of long term inotropic therapy with amrinone in patients with severe chronic heart failure. *Circulation* 1984; 70: 1038-1047.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

31. Packer M, Medina N, Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. *Circulation* 1985; 71: 761-766.
32. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Krebs C, Likoff M, Packer M, for the Amrinone Multicenter Study Group. Long-term oral amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. *Circulation* 1985; 71: 963-971.
33. Packer M, Medina N, Yushak, Lee WH. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure. Results of a randomized, crossover study. *Am Heart J* 1985; 109: 1293-1299.
34. Packer M, Lee WH, Medina N, Yushak M. Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. *J Am Coll Cardiol* 1985; 6: 635-645.
35. Packer M, Medina N, Yushak M, Lee WH. Usefulness of plasma renin activity in predicting hemodynamic and clinical responses and survival during long-term converting-enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. *Br Heart J* 1985; 54: 298-304.
36. Packer M, Medina N, Yushak M. Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure. *Am J Med Sci* 1986; 291: 8-15.
37. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. *Circulation* 1986; 73: 257-267.
38. Packer M, Lee WH, Medina N, Yushak M. Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. *Ann Intern Med* 1986; 104: 147-154.
39. Packer M, Medina N, Yushak M, Lee WH. Hemodynamic factors limiting the response to transdermal nitroglycerin in patients with severe chronic congestive heart failure. *Am J Cardiol* 1986; 57: 260-267.
40. Packer M, Lee WH. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in patients with severe chronic heart failure. *Am J Cardiol* 1986; 57: 347-348.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

41. Packer M, Medina N, Yushak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. *J Am Coll Cardiol* 1986; 7: 671-680.
42. Packer M, Lee WH, Medina N, Yushak M. Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. *Am J Cardiol* 1986; 57: 853-858.
43. Packer M, Medina N, Yushak M. Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1986; 57: 1323-1328.
44. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. *N Engl J Med* 1986; 315: 847-853.
45. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. *Circulation* 1986; 74: 766-774.
46. Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. *Am Heart J* 1987; 113: 137-143.
47. Packer M, Lee WH, Medina M, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril or enalapril for severe chronic heart failure. *Ann Intern Med* 1987; 106: 346-354.
48. Packer M, Lee WH, Medina N, Yushak M, Kessler PD, Gottlieb SS. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting-enzyme inhibition in patients with severe chronic heart failure. *Am J Med* 1987; 82: 1119-1126.
49. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. *N Engl J Med* 1987; 317: 799-804.
50. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting-enzyme inhibition in severe chronic heart failure. *J Am Coll Cardiol* 1987; 10: 837-844.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

51. Packer M, Lee WH, Medina N, Yushak M, Bernstein JL, Kessler PD. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. *J Am Coll Cardiol* 1987; 10: 1303-1311.
52. Kessler PD, Packer M, Medina N, Yushak M. Cumulative hemodynamic response to short-term therapy with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic heart failure. *J Cardiovasc Pharmacol* 1988; 12: 6-11.
53. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. *Ann Intern Med* 1989; 110: 505-509.
54. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. *J Am Coll Cardiol* 1989; 13: 1534-1539.
55. Gottlieb SS, Packer M. Deleterious hemodynamic effect of lidocaine in congestive heart failure. *Am Heart J* 1989; 118: 611-612.
56. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, Goldstein S, for the Captopril-Digoxin Study Group. Predictors of total mortality and sudden death in mild to moderate heart failure. *J Am Coll Cardiol* 1989; 14: 564-570.
57. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Comparative hemodynamic effects of procainamide, tocainide and encainide in chronic heart failure. *Circulation* 1990; 81: 860-864.
58. Coplan NL, Shimony RY, Ioachim H, Wilentz JR, Posner D, Lipschitz A, Ruden RA, Sherrid MV, Gaetz H, Kukin ML, Packer M. Primary pulmonary hypertension in association with the acquired immunodeficiency syndrome. *Am J Med* 1990; 89: 96-99.
59. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. *N Engl J Med* 1990; 323: 236-241.
60. Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. *J Am Coll Cardiol* 1990; 16: 827-831.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

61. Neuberg GW, Kukin ML, Pinsky DJ, Medina N, Yushak M, Packer M. Hemodynamic effects of renin inhibition in severe chronic heart failure. *Am J Cardiol* 1991; 67: 63-66.
62. Haber HL, Leavy JA, Kessler PD, Kukin ML, Gottlieb SS, Packer M. The erythrocyte sedimentation rate in congestive heart failure. *N Engl J Med* 1991; 324: 353-358.
63. Pfeffer MA, Moye LA, Braunwald E, Basta L, Borwn EJ, Cuddy TE, Dagenais GR, Flaker GC, Geltman EM, Gersh BJ, Goldman S, Lamas GA, Packer M, Rouleau JL, Rutherford JD, Steingart RM, Wertheimer JH for the SAVE Investigators. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. *JAMA* 1991; 266: 528-532.
64. Steingart RM, Packer M, Hamm P, Coglianesi ME, Kukin ML, Moye L, Sollano J, Lewis S, Gersh B, Geltman E, Kantrowitz N, Katz S, Pfeffer M for the SAVE Investigators. Sex bias in the management of coronary artery disease. *N Engl J Med* 1991; 325: 226-230.
65. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, and the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. *N Engl J Med* 1991; 325: 1468-1475.
66. Pfeffer MA, Braunwald E, Moyé LA, Rutherford J, Basta L, Brown EJ, Cuddy TE, Geltman EM, Goldman S, Flaker G, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. *N Engl J Med* 1992; 327: 669-677.
67. Eichhorn EJ, Tandon PK, DiBianco R, Timmis GC, Fenster PE, Shannon J, Packer M. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. *J Am Coll Cardiol* 1993; 21: 634-640.
68. Packer M, Gheorghide M, Young JB, Smith LK, Costantini PJ, Adams KF, Cody RJ, Gourley LA, Jolly MK for the RADIANCE Study. Withdrawal of digoxin in patients with chronic heart failure treated with converting-enzyme inhibitors. *N Engl J Med* 1993; 329: 1-7.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

69. Gupta SK, Granneman GR, Packer M, Boger RS. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662), a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure. *J Cardiovasc Pharmacol* 1993; 21: 834-40.
70. Packer M, Narahara KA, Elkayam U, Sullivan JM, Pearle DL, Massie BM, Creager MA, and the Principal Investigators of the REFLECT Study. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. *J Am Coll Cardiol* 1993; 22: 65-72.
71. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye LA, Packer M, Dagenais GR, Sussex B, Arnold M, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Pfeffer M. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. *J Am Coll Cardiol* 1993; 22: 390-398.
72. Massie BM, Berk MR, Brozena SC, Elkayam U, Plehn JF, Kukin ML, Murphy BE, Neuberg GW, Steingart RM, Packer M, DeHaan H for the FACET Investigators. Can further benefit can be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and angiotensin converting enzyme inhibitor therapy? Results of the flosequinan — ACE inhibitor trial (FACET). *Circulation* 1993; 88: 492-501.
73. Gottlieb SS, Kukin ML, Penn J, Fisher ML, Cines M, Medina N, Yushak M, Taylor M, Packer M. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. *J Am Coll Cardiol* 1993; 22: 963-967.
74. Hall C, Rouleau JL, Moye L, deChamplain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, Lamas GA, Sestier F, Gottlieb SS, Wun C-C C, Pfeffer MA. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. *Circulation* 1994; 89: 1934-1942.
75. Rouleau JL, Packer M, Moye L, deChamplain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, et al. Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. *J Am Coll Cardiol* 1994; 24: 583-591.
76. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. *Circulation* 1994; 90: 1731-1738.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

77. Horn EM, Kukin ML, Neuberg GW, Goldsmith RL, McCarty M, Gratch M, Medina N, Yushak M, Packer M, Bilezikian JP. Lymphocyte G proteins reflect response to treatment in congestive heart failure. *Am Heart J* 1995; 129: 98-106.
78. Krum H, Bigger JT Jr, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. *J Am Coll Cardiol* 1995; 25: 289-294.
79. Krum H, Sackner-Bernstein JD, Goldsmith R, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HL, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in severe chronic heart failure. *Circulation* 1995; 92: 1499-1506.
80. Levin HL, Oz M, Rose EA, Packer M, Burkhoff D. Reversal of ventricular remodelling in patients with chronic heart failure by prolonged mechanical unloading. *Circulation* 1995; 91: 2717-2720.
81. Levin HR, Chen JM, Oz MC, Catanese KA, Krum H, Goldsmith RL, Packer M, Rose EA. Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. *Ann Thorac Surg* 1994; 58: 1515-1520.
82. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. *Am J Cardiol* 1995; 75: 1282-1283.
83. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. *Am Heart J* 1996; 131: 337-341.
84. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; 334: 1349-1355.
85. Massie BM, Shah NB, Pitt B, Packer M. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flecainide. *Am Heart J* 1996; 132: 130-136.
86. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1997; 336: 1023-1024.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

87. Todaka K, Wang J, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. *J Pharmacol Exper Ther* 1996; 279: 120-127.
88. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. *Circulation* 1996; 94: 2793-2799.
89. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation* 1996; 94: 2800-2806.
90. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. *Circulation* 1996; 94: 3184-3189.
91. Adams KF Jr, Gheorghide M, Uretsky BF, Young JB, Ahmed S, Tomasko L, Packer M. Patients with mild heart failure worsen during withdrawal from digoxin therapy. *J Am Coll Cardiol* 1997; 30: 42-48.
92. Knecht M, Burkhoff D, Yi GH, Popilskis S, Homma S, Packer M, Wang J. Coronary endothelial dysfunction precedes heart failure and reduction in coronary reserve in awake dogs. *J Mol Cell Cardiol* 1997; 29: 217-227.
93. Todaka K, Wang J, Knecht M, Stennett R, Packer M, Burkhoff D. Impact of exercise training on ventricular properties in a canine model of congestive heart failure. *Am J Physiol* 1997; 272: H1382-1390.
94. Todaka K, Leibowitz D, Homma S, Fisher PE, Derose C, Stennett R, Packer M, Burkhoff D. Characterizing ventricular mechanics and energetics following repeated coronary microembolization. *Am J Physiol* 1997; 272: H186-194.
95. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. *J Cardiac Failure* 1997; 3: 173-179.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

96. Goldsmith RL, Bigger JT, Bloomfield DM, Krum H, Steinman RC, Sackner-Bernstein J, Packer M. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. *Am J Cardiol* 1997; 80: 1101-1104.
97. Wang J, Yi GH, Knecht M, Cai BL, Poposkis S, Packer M, Burkhoff D. Physical training alters the pathogenesis of pacing-induced heart failure through endothelium-mediated mechanisms in awake dogs. *Circulation* 1997; 96: 2683-2692.
98. Massie BM, Cleland JG, Armstrong PW, Packer M, Poole-Wilson PA, Lars R for the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. *J Cardiac Failure* 1998; 4: 3-8.
99. Adams KF Jr, Gheorghide M, Uretsky BF, Young JB, Patterson JH, Tomasko L, Packer M. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. *Am Heart J* 1998; 135: 389-397.
100. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. *Circulation* 1998; 98: 1184-1191.
101. Cleland JGF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryden L. Baseline clinical characteristics of patients recruited into the Assessment of Treatment with Lisinopril and Survival study. *Eur J Heart Failure* 1999; 1: 73-79.
102. Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, Levitan RG, Weinberg AD, Stevenson LW, Shapiro PA, Lazar RM, Watson JT, Goldstein DJ, Gelijns AC. The REMATCH trial: rationale, design, and endpoints. *Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure*. *Ann Thor Surg* 1999; 67: 723-730.
103. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. *Circulation* 1999; 100: 2312-2318.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

104. Teerlink JR, Jalaluddin M, Anderson S, Kukin ML, Eichhorn EJ, Francis G, Packer M, Massie BM for the PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. *Circulation* 2000; 101: 40-6.
105. Udelson JE, DeAbate CA, Berk M, Neuberg G, Packer M, Vijay NK, Gorwitt J, Smith WB, Kukin ML, LeJemtel T, Levine TB, Konstam MA. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. *Am Heart J* 2000;139: 503-10.
106. Moe GW, Rouleau JL, Charbonneau L, Proulx G, Arnold JM, Hall C, de Champlain J, Barr A, Sirois P, Packer M. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. *Am Heart J* 2000; 139: 587-95.
107. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. *Circulation* 2000; 102: 611-6.
108. Carson PA, O'Connor CM, Miller AB, Anderson S, Belkin R, Neuberg GW, Wertheimer JH, Frid D, Cropp A, Packer M. Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. *J Am Coll Cardiol* 2000; 36: 541-6.
109. Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. *Eur Heart J* 2000; 21: 1967-78.
110. Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial. *Arch Intern Med* 2001; 161: 165-71.
111. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med* 2001; 344: 1358-65.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

112. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M for U.S. Carvedilol Heart Failure Study Group. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. *J Am Coll Cardiol* 2001; 37: 1692-9.
113. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. *Am Heart J* 2001; 141: 899-907.
114. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344:1651-8.
115. Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryden L for the ATLAS Investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. *Eur Heart J* 2001;22:1601-12.
116. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J for the MIRACLE Study Group. *N Engl J Med*. 2002;346:1845-53.
117. Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M for the PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. *Am Heart J* 2002;144:31-8
118. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). *Circulation* 2002;106:920-6.
119. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002;106:2194-9.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

120. Hansen MS, Stanton EB, Gawad Y, Packer M, Pitt B, Swedberg K, Rouleau JL, for the Canadian PROFILE Investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. *Am J Cardiol* 2002;90:969-73.
121. Vittorio TJ, Lang CC, Katz SD, Packer M, Mancini DM, Jorde UP. Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. *Circulation* 2003;107:290-3
122. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. *JAMA* 2003;289:712-8.
123. Rouleau JL, Pitt B, Dhalla NS, Dhalla KS, Swedberg K, Hansen MS, Stanton E, Lapointe N, Packer M. Canadian Prospective Randomized Flosequinan Longevity Evaluation Investigators. Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. *Am. Heart J.* 2003;145:926-32.
124. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, inpatients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. *Circulation* 2003;107:3133-40.
125. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. *Am J Hypertens* 2004;17:103-11.
126. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. *Eur J. Heart Fail* 2004;6:343-50.
127. Wu AH, Packer M, Smith A, Bijou R, Fink D, Mair J, Wallentin L, Johnston N, Feldcamp CS, Haverstick DM, Ahnadi CE, Grant A, Depres N, Bluestein B, Ghani F. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. *Clin Chem* 2004;50:867-73.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

128. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004;109:1594-602.
129. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M. Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. *J Am Coll Cardiol*. 2004;43:1423-9.
130. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design and baseline patient characteristics. *J Card Fail* 2004;10:101-12.
131. Majumdar SR, McAlister FA, Cree M, Chang WC, Packer M, Armstrong PW; ATLAS Study Group. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) Study. *Clin Ther* 2004;26:694-703.
132. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. *Circulation* 2004;110:1780-6.
133. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. *Circulation* 2004;110:3667-73.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

134. Stanton EB, Hansen MS, Sole MJ, Gawad Y, Packer M, Pitt B, Swedberg K, Rouleau JL; PROFILE investigators. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. *Can J Cardiol* 2005;21:39-43.
135. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. *J Card Fail* 2005;11:12-20.
136. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. *J Card Fail* 2005;11:177-87.
137. Stewart S, McMurray JJ, Hebborn A, Coats AJ, Packer M; the COPERNICUS Study Group. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. *Int J Cardiol* 2005;100:143-9.
138. Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. *Eur Heart J* 2005;26:2154-8.
139. Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA; OVERTURE Investigators. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. *Am Heart J* 2005;150:257-62.
140. Patingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 2005;122:927-39.
141. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, DeMets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. *J Card Fail* 2005;11:12-20.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

142. Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. *Am Heart J.* 2006;151:55-61.
143. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation.* 2006;113:1424-33.
144. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, O'Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA; Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. : *J Am Coll Cardiol.* 2006;47:2245-52.
145. Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH; 369 Study Group. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. *Am J Cardiol.* 2006;98(7A):39-45.
146. Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, Cohn J, Goldstein S, Douglas PS. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. *J Am Coll Cardiol.* 2007;49:1450-8.
147. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Pöder P, Kivikko M; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. *JAMA.* 2007;297:1883-91.
148. Tam SW, Sabolinski ML, Worcel M, Packer M, Cohn JN. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. *Clin Pharmacokinet.* 2007;46:885-95.
149. Friedewald VE Jr, Bennett JS, Packer M, Roberts WC, Williams GW. The editor's roundtable: nonsteroidal antiinflammatory drugs and cardiovascular risk. *Am J Cardiol.* 2008 Oct 15;102(8):1046-55.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

150. Singal AG, Yopp A, Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. *J Gen Intern Med.* 2012;27:861-7.
151. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, Hill JA, Virgin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine B. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature.* 2012;481:511-5.
152. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejection fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet.* 2012;380:1387-95.
153. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T for the REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. *JACC Heart Fail* 2013;1:103-111.
154. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau J-L, Schocken D, Anderson SA, DeMets DL for the PRAISE-2 Study Group. Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy : Results of the PRAISE-2 Study (Prospective Randomized Amlodipine Survival Evaluation 2). *JACC Heart Fail* 2013; 1: 308-314.
155. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Fail.* 2013;15:1062-73.
156. Santos AB, Kraigher-Krainer E, Bello N, Claggett B, Zile MR, Pieske B, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Shah AM, Solomon SD. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. *Eur Heart J.* 2014;35:42-7.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

157. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2014;63:447-56.
158. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. *Eur J Heart Fail*. 2014;16:535-42.
159. Jhund PS, Claggett B, Packer M, Zile MR, Voors AA, Pieske B, Lefkowitz M, Shi V, Bransford T, McMurray JJ, Solomon SD. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. *Eur J Heart Fail*. 2014;16:671-7.
160. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Fail*. 2014;16:817-25.
161. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Solomon SD; for the PARAMOUNT Investigators. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. *Eur Heart J*. 2014;35:3442-51
162. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*. 2014;32:2380-5.
163. Santos ABS, Kraigher-Krainer E, Gupta DK, Claggett B, Zile MR, Burkert P, Voors AA, Lefkowitz M, Bransford T, Shi V, Packer M, McMurray JJV, Shah AM, Solomon SD, for the PARAMOUNT Investigators. Impaired left atrial function in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2014;16:1096-103.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

164. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR on behalf of the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition compared with enalapril in heart failure. *N Engl J Med* 2014;371:993-1004.
165. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, González-Medina A, Hagege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, for the PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation*. 2015;131:54-61.
166. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. *Circ Heart Fail*. 2014;7:953-9.
167. McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Bělohávek J, Böhm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R; on behalf of the PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. *Eur Heart J*. 2015;36:434-9.
168. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross T, Hibshoosh H, Xiao, G, Packer M, Xie Y, Levine B. Decreased expression of BECN1 in breast cancer is associated with ER-negative subtypes and poor prognosis. *EBioMedicine*. 2015; 2:255-263.
169. Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD; for the PARAMOUNT Investigators. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail*. 2015;17:510-7.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

170. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. *Eur Heart J*. 2015;36:1990-7.
171. McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. *Eur Respir J*. 2015;46:405-13.
172. Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. *Eur Heart J*. 2015;36:2576-84.
173. Kotsia AP, Rangan BV, Christopoulos G, Coleman A, Roesle M, Ciper D, de Lemos JA, McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of extended-release niacin on saphenous vein graft atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. *J Invasive Cardiol*. 2015;27:E204-10.
174. Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJ, Packer M, Solomon SD for the PARADIGM-HF Investigators and Committees. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. *J Am Coll Cardiol*. 2015;66:2059-71.
175. Guerra A, Rangan BV, Coleman A, Xu H, Kotsia A, Christopoulos G, Sosa A, Chao H, Han H, Abdurrahim G, Roesle M, de Lemos JA, McGuire DK, Packer M, Banerjee S, Brilakis ES. Effect of extended-release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell mobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. *J Invasive Cardiol*. 2015;27:555-60.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

176. Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD; PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan. *N Engl J Med*. 2015;373:2289-90.
177. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; PARADIGM-HF Investigators. Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF Trial. *JACC Heart Fail*. 2016;4:152-8.
178. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. *Circ Heart Fail*. 2016 Jan;9(1). pii: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.
179. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circ Heart Fail*. 2016 Mar;9(3):e002744. doi: 10.1161/CIRCHEARTFAILURE.115.002744.
180. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD; Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. *BMJ*. 2016 Apr 20;353:i1855. doi: 10.1136/bmj.i1855.
181. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). *Circulation*. 2016 Apr 20. pii: CIRCULATIONAHA.115.020729. [Epub ahead of print]

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

182. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJ. Efficacy of sacubitril/valsartan relative to a prior decompensation: The PARADIGM-HF Trial. *JACC Heart Fail.* 2016;4:816-822.
183. Kristensen SL, Martinez F, Jhund PS, Arango JL, Bělohávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ. Geographic variations in the PARADIGM-HF heart failure trial. *Eur Heart J.* 2016;37:3167-3174.
184. Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, Zile M, Lefkowitz M, Shi V, Packer M. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF Trial. *Circ Heart Fail.* 2016 Jun;9(6). pii: e002735. doi: 10.1161/CIRCHEARTFAILURE.115.002735.
185. Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J, McMurray JJ, Solomon SD for the PARADIGM-HF Investigators. Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. *J Am Coll Cardiol.* 2016;68:241-8.
186. Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. *J Am Coll Cardiol.* 2016;68:2425-2436.
187. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD for the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. *Eur J Heart Fail.* 2016;18:1228-1234.
188. Nadruz W Jr, Claggett BL, McMurray JJ, Packer M, Zile MR, Rouleau JL, Desai AS, Swedberg K, Lefkowitz M, Shi VC, Prescott MF, Solomon SD. Impact of body mass index on the accuracy of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide for predicting outcomes in patients with chronic heart failure and reduced ejection fraction: Insights from the PARADIGM-HF study (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). *Circulation.* 2016;134:1785-1787.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

189. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees. Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. *Circ Heart Fail.* 2016 Sep;9(9). pii: e003212. doi: 10.1161/CIRCHEARTFAILURE.116.003212.
190. Packer M, Holcomb R, Abraham WT, Anker S, Dickstein K, Filippatos G, Krum H, Maggioni AP, McMurray JJ, Mebazaa A, O'Connor C, Peacock F, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Holzmeister J; TRUE-AHF Investigators and Committees. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. *Eur J Heart Fail.* 2017;19:673-681.
191. Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. *Eur J Heart Fail.* 2017;19:129-137.
192. Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. *JAMA Cardiol.* 2017;2:79-85.
193. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJ. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. *Eur Heart J.* 2017;38:1132-1143.
194. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Influence of sacubitril/valsartan on glycemic control in patients with heart failure and diabetes mellitus: a post hoc analysis of the PARADIGM-HF trial. *Lancet Diab Endocrin* 2017;5:333-340.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

195. Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets PhD DL, Kobrin I, Roux S, Swedberg K, on behalf of the ENABLE Investigators and Committees. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. *JACC Heart Fail* 2017;5:317-326.
196. Packer M, Pitt B, Rouleau J-L, Swedberg K, DeMets DL, Fisher L. Long-term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the PROFILE trial after 24 years. *JACC Heart Fail* 2017;5:399-407
197. Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker S, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock F, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J on behalf of the TRUE-AHF Investigators and Committees. Effect of ularitide on cardiovascular mortality in acute heart failure. *N Engl J Med* 2017;376:1956-1964.
198. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile M, McMurray JJV. Declining risk of sudden death in heart failure. *N Engl J Med* 2017;377:41-51.
199. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. *JACC Heart Fail* 2017;5:471-482
200. Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV; PARADIGM-HF Investigators and Committees. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. *Am Heart J*. 2017;188:35-41.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

201. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. *J Am Coll Cardiol.* 2017;69:2885-2896.
202. Clark AL, Coats AJ, Krum H, Katus HA, Mohacsi P, Salekin D, Schultz MK, Packer M, Anker SD. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. *J Cachexia Sarcopenia Muscle.* 2017;8:549-556.
203. Lewis EF, Claggett BL, McMurray JV, Packer M, Lefkowitz MP, Rouleau J-L, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-related quality of life outcomes in PARADIGM-HF. *Circ Heart Fail* 2017 Aug;10(8). pii:e003430. doi:10.1161/CIRCHEARTFAILURE.116.003430.
204. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018;39:26-35.
205. Shen L, Ramires F, Martinez F, Abraham WT, Dickstein K, Køber L, Packer M, Rouleau J-L, Solomon SD, Swedberg K, Zile MR, Jhund PS, Gimpelewicz CR, McMurray JJV on behalf of the PARADIGM-HF and ATMOSPHERE Investigators and Committees. Contemporary characteristics and outcomes in Chagas heart failure compared with other non-ischemic and ischemic cardiomyopathy. *Circ Heart Fail* 2017 Nov;10(11). pii: e004361. doi: 10.1161/CIRCHEARTFAILURE. 117.004361.
206. Chandra A, Lewis E, Claggett B, Desai A, Packer M, Zile M, Swedberg K, Rouleau J-L, Shi V, Lefkowitz MP, Katova T, McMurray JJV, Solomon S. Effects of sacubitril/valsartan on physical and social activity limitations in heart failure patients: the PARADIGM-HF trial. *JAMA Cardiol* 2018;3:498-505.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

207. Kristensen SL, Jhund P, Mogensen UM, Rørth R, Abraham WT, Desai A, Dickstein K, Rouleau J-L, Zile MR, Swedberg K, Packer M, Solomon SD, Køber L, McMurray JJV on behalf of the PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic value of N-terminal pro B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. *Circ Heart Fail*. 2017;Oct;10(10). pii: e004409. doi: 10.1161/CIRC.HeartFailure.117.004409.
208. Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Køber L, McMurray JJV; on behalf of the PARADIGM-HF and ATMOSPHERE Investigators and Committees. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. *J Am Coll Cardiol* 2017;70:2490-2500.
209. Mogensen UM, Køber L, Jhund PS, Desai A, Senni M, Kristensen SL, Dukát A, Chen C-H, Ramires F, Lefkowitz MP, Prescott M, Shi VC, Rouleau J-L, Solomon SD, Swedberg K, Packer M, McMurray JJV, on behalf of the PARADIGM-HF Investigators and Committees. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. *Eur J Heart Fail* 2018;20:514-522.
210. Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Fail*. 2018;20:760-768.
211. Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau J, Zile M, Swedberg K, Solomon SD. Natriuretic peptides as predictive biomarkers of treatment response in clinical trials of heart failure. *JACC Heart Fail* 2018;6:564-569.
212. Packer M, Claggett BL, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. *Lancet Diabetes Endocrinol* 2018;6:547-554
213. Damman K, Gori M., Claggett B, Jhund P, Senni M, Lefkowitz MP, Prescott M, Shi VC, Rouleau J-L, Swedberg K, Zile MR, Packer M, Desai AD, Solomon SD, McMurray JJV. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. *JACC Heart Fail* 2018;6:489-498.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

214. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai A, Packer M, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, MD, Solomon SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). *Circ Heart Fail*. 2018 Apr;11(4):e004745. doi: 10.1161/CIRCHEARTFAILURE.117.004745.
215. O'Meara E, M.F. Prescott MF, Claggett BL, Rouleau J-L, Chiang LM, S.D. Solomon SD, Swedberg K, Packer M, McMurray JJV, Zile MR. Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial. *Circ Heart Fail* 2018 May;11(5):e004446. doi: 10.1161/CIRCHEARTFAILURE.117.004446.
216. Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen C-H, Chopra VK, Cleland J, Comin-Colet J, Duengen H-D, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Saraiva JFK, Køber L, Lelonek M, Linssen G, Lund LH, Meara EO, Merkely B, Milicic D, Oh B-H, Perrone SV, Ranjith N, Saito Y, Shah S, Seferovic PM, Senni M, Sibulo AS, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Baseline characteristics of patients with heart failure and preserved ejection fraction: The PARAGON-HF Trial. *Circ Heart Fail* 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.
217. Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. *Eur J Heart Fail*. 2018;20:1701-1709.
218. Januzzi JL, Packer M, Claggett B, Liu J, Shah AM, Zile MR, Pieske B, Voors A, Gandhi PU, Prescott MF, Shi V, Lefkowitz JJV, Solomon SD. IGFBP7 (Insulin-like growth factor-binding protein-7) and neprilysin inhibition in patients with heart failure. *Circ Heart Fail*. 2018;11:e005133. doi: 10.1161/CIRCHEARTFAILURE.118.005133.

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

219. Ramires FJA, Martinez F, Gómez EA, Demacq C, Gimpelewicz CR, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. *ESC Heart Fail.* 2018;5:1069-1071.
220. Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Desai AS, Rouleau JL, Swedberg K, Fonorow GC. Estimated 5-Year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. *JAMA Cardiol* 2018 Nov 28. doi: 10.1001/jamacardio.2018.3957.
221. Rørth R, Jhund PS, Kristensen SL, Desai AS, Køber L, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. The prognostic value of troponin T and N terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. *Eur J Heart Fail* 2019;21:40-49.
222. Dewan P, Rørth R, Jhund PS, Shen Li, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Differential impact of heart failure with reduced ejection fraction on men and women. *J Am Coll Cardiol* 2019;73:29-40.
223. Dewan P, Jhund PS, Ferreira JP, Zannad F, Shen L, Køber L, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Income-inequality and outcomes in heart failure: a global between-country analysis. *JACC Heart Fail.* 2019;7:336-346.
224. Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Plasma biomarkers that reflect extracellular matrix regulatory mechanisms, collagen synthesis and processing in patients with heart failure and a reduced ejection fraction: Prognostic implications and effects of sacubitril / valsartan. *J Am Coll Cardiol* 2019;73:795-806

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

225. Dewan P, Jhund PS, Shen Li, Petrie M, Abraham WT, Atif Ali M, Chen C-H, Desai AS, Dickstein K, Huang J, Kiatchoosakun S, Kim K-S, Køber L, Lai W-T, Liao Y, Mogensen UM, B-O, Packer M, Rouleau JL, Shi V, Sibulo Jr AS, Solomon SD, Sritara P, Swedberg K, Tsutsui H, Zile MR, McMurray JJV. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. *Eur J Heart Fail*. 2018 Dec 10. doi: 10.1002/ejhf.1347. [Epub ahead of print]
226. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. *Eur J Heart Fail* 2019;21:337-341
227. Zile MR, O'Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray JJV, Shi V, Lefkowitz M, Rouleau J. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFREF. *J Am Coll Cardiol*. 2019 Feb 26;73:795-806.
228. Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M; Shi V, McMurray JJV, Solomon SD. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. *J Am Coll Cardiol* 2019;73:1264-1272.
229. Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Outcomes and effect of treatment according to etiology: an analysis of PARADIGM-HF. *JACC Heart Fail* 2019;7:457-465.
230. Qamer SZ, Malik A, Bayoumi EM, Lam PH, Singh S, Packer M, Kanonidis IE, Morgan CJ, Abdelmawgoud A, Allman RM, Fonarow GC, Ahmed A. Digoxin use and outcomes in older patients with heart failure with reduced ejection fraction. *Am J Med*. 2019 May 28. pii: S0002-9343(19)30443-7. doi: 10.1016/j.amjmed.2019.05.012
231. Lam PH, Packer M, Fonarow GC, MD, Faselis C, Morgan CJ, Pitt B, Ahmed A. Early effects of starting doses of enalapril in patients with chronic heart failure: results from the SOLVD Treatment trial. *Am J Med* 2019 Aug 8. pii: S0002-9343(19)30615-1. doi: 10.1016/j.amjmed.2019.06.053.
232. Qamer SZ, Malik A, Bayoumi EM, Lam PH, Singh S, Packer M, Kanonidis IE, Morgan CJ, Abdelmawgoud A, Allman RM, Fonarow GC, Ahmed A. Digoxin use and outcomes in older patients with heart failure with reduced ejection fraction. *Am J Med*. 2019 May 28. pii: S0002-9343(19)30443-7. doi: 10.1016/j.amjmed.2019.05.012

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

233. Solomon SD, Anand IS, Ge J, MD, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund P, Boytsov SA, Colet JC, Cleland J, Duengen H-D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, McMurray JJV, for the PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019 Sep 1. doi: 10.1056/NEJMoa1908655
234. Selvaraj S, Claggett B, Pozzi A, MD; McMurray JJV, Jhund P, Packer M, Desai AS, Lewis EF, Vaduganathan M, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Solomon SD. Prognostic implications of the cardiovascular physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. *Circulation* 2019 Sep 12. doi: 10.1161/CIRCULATIONAHA.119.039920. [Epub ahead of print]
235. Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Shi VC, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD on behalf of the PARAGON-HF Investigators. Health-related quality of life in heart failure with preserved ejection fraction and comparison with heart failure with reduced ejection fraction: the PARAGON-HF trial. *JACC Heart Fail* 2019 Jul 10. pii: S2213-1779(19)30409-3. doi: 10.1016/j.jchf.2019.05.015.
236. Malik A, Masson R, Singh S, Wu W-C, Packer M, Pitt B, Morgan CJ, Allman RM, Fonarow GC, Ahmed A. Digoxin discontinuation and outcomes in hospitalized older patients with heart failure with reduced ejection fraction. *J Am Coll Cardiol* (in press)
237. Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Anker SD. Evaluation of the effect of SGLT2 inhibition with empagliflozin on the morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. *Eur J Heart Fail* (in press)
238. Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupón J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Núñez J, de Boer RA, Bayés-Genís A. Unravelling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. *JACC Basic Transl Sci* (in press)

Milton Packer, M.D.

ORIGINAL RESEARCH ARTICLES (PEER-REVIEWED)

239. Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT pro BNP in patients with heart failure and reduced ejection fraction. *Circ Heart Fail* (in press)
240. Packer M. Methodological and clinical heterogeneity and extraction errors in meta-analyses of catheter ablation for atrial fibrillation in heart failure. *J Am Heart Assoc* (in press)
241. Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M on behalf of the EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effect of SGLT2 inhibition with empagliflozin on the morbidity and mortality of patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial. *Eur J Heart Fail* (in press)
242. Kotecha D, Gill S, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJ, Wikstrand J, Anker S, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JG, Damman K, Redon J, Baigent C, Coats AJ on behalf of the Beta-blockers in Heart Failure Collaborative Group. Beta-blockers are effective in high-risk heart failure patients with reduced ejection fraction, sinus rhythm and moderately-severe renal dysfunction. *J Am Coll Cardiol* (in press)
243. O'Donnell M, Mentz A, Alderman MH, Brady A, Califf RM, Diaz R, Gupta R, López-Jaramillo P, Luft FC, Lüscher TF, Mancina G, Mann JFE, McCarron D, McKee M, Messerli FH, Moore L, Narula J, Oparil S, Packer M, Prabhakaran D, Schutte AE, Sliwa K, Staessen JA, Thomas M, Yancy C, Yusuf S. Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. *Eur Heart J* (in press)

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES (OF 465 PAPERS) [PEER-REVIEWED]

- R1. Packer M, Meller J. Oral vasodilator therapy for chronic heart failure. A plea for caution. *Am J Cardiol* 1978; 42: 686-689.
- R2. Packer M. Is there a drug of choice for vasodilator therapy in patients with refractory heart failure? *Chest* 1980; 77: 7-9.
- R3. Packer M, Le Jemtel TH. Pharmacologic and physiologic determinants of vasodilator response. A conceptual framework for rational drug therapy for chronic heart failure. *Prog Cardiovasc Dis* 1982; 24: 275-292.
- R4. Packer M. Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification. *Drugs* 1982; 24: 64-74.
- R5. Packer M, Frishman W. Verapamil therapy for stable and unstable angina pectoris. Calcium antagonists in perspective. *Am J Cardiol* 1982; 50: 881-885.
- R6. Singh BN, Chew CYC, Josephson MA, Packer M. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil relative to its pharmacologic and hemodynamic properties. *Am J Cardiol* 1982; 50: 886-893.
- R7. Packer M, Leon MB, Bonow RO, Kieval J, Rosing DR, Bala Subramanian V. Hemodynamic and clinical effects of combined therapy of verapamil and propranolol in patients with angina pectoris. *Am J Cardiol* 1982; 50: 903-912.
- R8. Packer M, Medina N, Yushak M. Contrasting hemodynamic responses in severe heart failure: a comparison of captopril and other vasodilator drugs. *Am Heart J* 1982; 104: 1215-1223.
- R9. Cohen M, Packer M, Gorlin R. Indications for ventricular aneurysmectomy. *Circulation* 1983; 67: 717-722.
- R10. Packer M. New perspectives on the therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. *Am J Med* 1983; 74 (6B): 61-72.
- R11. Packer M. Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism. *J Am Coll Cardiol* 1983; 2: 841-852.
- R12. Packer M. Conceptual dilemmas in the classification of vasodilator drugs for severe heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent. *Am J Med* 1984; 76 (6A): 3-13.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R13. Packer M, Halperin JL, Brooks KM, Rothlauf E, Lee WH. Nitroglycerin therapy in the management of pulmonary hypertensive disorders. *Am J Med* 1984; 76 (6A): 67-75.
- R14. Packer M. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. *Int J Cardiol* 1985; 7: 111-120.
- R15. Packer M. Therapeutic application of calcium channel antagonists in the treatment of patients with pulmonary hypertension. *Am J Cardiol* 1985; 55: 196B-201B.
- R16. Packer M. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. *Ann Intern Med* 1985; 103: 258-270.
- R17. Packer M. Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure? The price we pay for interfering with evolution. *J Am Coll Cardiol* 1985; 6: 171-173.
- R18. Packer M. Mechanisms of nitrate action in patients with severe left ventricular failure. Conceptual problems with the theory of venosequestration. *Am Heart J* 1985; 110: 259-264.
- R19. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. *Circulation* 1985; 72: 681-685.
- R20. Packer M. Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy. *Chest* 1985; 88: 265S-268S.
- R21. Packer M, Gottlieb SS, Kessler PD. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. The basis of a new physiologic approach to control of arrhythmia. *Am J Med* 1986; 80 (4A): 23-29.
- R22. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. *Postgrad Med J* 1986; 62 (suppl 1): 179-182.
- R23. Packer M. Role of vasodilator therapy in the treatment of severe chronic heart failure: a rational approach. *Drugs* 1986; 32: suppl 5: 13-26.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R24. Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. *J Am Coll Cardiol* 1987; 9: 433-438.
- R25. Packer M, Gottlieb SS, Blum MA. Immediate and long-term pathophysiologic mechanisms in the genesis of sudden cardiac death in patients with congestive heart failure. *Am J Med* 1987; 82 (3A): 4-10.
- R26. Packer M. Prolonging life in patients with congestive heart failure: the next frontier. *Circulation* 1987; 75: suppl IV: 1-3.
- R27. Packer M, Leier CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. *Circulation* 1987; 75: suppl IV: 55-63.
- R28. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin M. Role of neurohormonal mechanisms in determining the survival of patients with severe chronic heart failure. *Circulation* 1987; 75: suppl IV: 80-92.
- R29. Packer M. Do vasodilators prolong life in heart failure? *N Engl J Med* 1987; 316: 1471-1473.
- R30. Packer M, Lee WH, Kessler PD, Gottlieb SS. Can we expect vasodilator therapy to prolong life in patients with congestive heart failure? *J Cardiovasc Pharmacol* 1987; 9 (suppl 2): S73-S75.
- R31. Packer M, Kessler PD, Lee WH. Calcium channel blockade in the management of severe chronic congestive heart failure: a bridge too far. *Circulation* 1987; 75: suppl V: 56-64.
- R32. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. *Am J Cardiol* 1987; 60: 179-184.
- R33. Packer M. Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure. *Am J Kidney Dis* 1987; 10: suppl 1: 66-73.
- R34. Packer M. Converting-enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts. *J Cardiovasc Pharmacol* 1987; 10 (suppl 7): S83-S87.
- R35. Packer M. Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system. *Postgrad Med* 1988; 83 (Feb 29 suppl): 96-103.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R36. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. *Circulation* 1988; 77: 721-730.
- R37. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. *Circulation* 1988; 77 (suppl I): 64-73.
- R38. Packer M. Clinical trials in congestive heart failure: why do studies report conflicting results? *Ann Intern Med* 1988; 109: 3-5.
- R39. Packer M. Therapeutic challenges in the management of congestive heart failure. *J Am Coll Cardiol* 1988; 12: 262-264.
- R40. Packer M. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? Protagonist's viewpoint. *J Am Coll Cardiol* 1988; 12: 562-566.
- R41. Packer M. Effects of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure. *Eur Heart J* 1988; 9 (suppl H): 105-108.
- R42. Packer M. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope. *J Am Coll Cardiol* 1988; 12: 1299-1317.
- R43. Packer M. Therapeutic options in the management of chronic heart failure: Is there a drug of first choice? *Circulation* 1989; 79: 198-204.
- R44. Packer M. Effect of phosphodiesterase inhibitors on the survival of patients with chronic heart failure. *Am J Cardiol* 1989; 63: 41A-45A.
- R45. Packer M. Does digitalis work in chronic heart failure? The end of a 200 year-old controversy. *Cardiovasc Drug Ther* 1989; 2: 743-746.
- R46. Packer M. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. *N Engl J Med* 1989; 320: 709-718.
- R47. Packer M. The clinical significance of nitrate tolerance in patients with congestive heart failure. *Eur Heart J* 1989; 10 (suppl A): 20-25.
- R48. Packer M. Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension? *Chest* 1989; 95: 1173-1174.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R49. Packer M. Is activation of the sympathetic nervous system beneficial or detrimental in chronic heart failure. Lessons from clinical trials with beta agonists and antagonists. *J Cardiovasc Pharmacol* 1989; 14 (suppl 5): S38-S43.
- R50. Packer M. Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure. *Cardiology* 1989; 76 (suppl 2): 50-55.
- R51. Packer M. Second-generation calcium channel blockers in the treatment of heart failure: are they any better than their predecessors? *J Am Coll Cardiol* 1989; 14: 1339-1342.
- R52. Packer M. Pathophysiologic mechanisms underlying the adverse effects of calcium channel blocking drugs in patients with chronic heart failure. *Circulation* 1989; 80 (suppl IV): 59-67.
- R53. Packer M, Kukin ML, Neuberg GW, Pinsky DJ, Penn J, Abittan MH. The current status of angiotensin converting enzyme inhibitors in the management of chronic heart failure. *J Hypertension* 1989; 7 (suppl 5): S33-S36.
- R54. Packer M. Why patients with heart failure fail to respond to treatment with vasodilator and inotropic drugs. *Cardiovasc Drug Ther* 1989; 3: 1055-1057.
- R55. Pratt CM, Brater CD, Harrell FE, Kowey PR, Leier CV, Lowenthal DT, Messerli F, Packer M, Pritchett ELC, Ruskin JN. Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial. *Am J Cardiol* 1990; 65: 103-105.
- R56. Packer M. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. *Circulation* 1990; 81 (suppl III): 78-86.
- R57. Packer M. Hormone-electrolyte interactions in congestive heart failure: Lessons from a 4000 year-old Sumerian tablet. *Am J Cardiol* 1990; 65: 1E-3E.
- R58. Packer M. Potential role for potassium as a determinant of morbidity and mortality in patients with hypertension and chronic heart failure. *Am J Cardiol* 1990; 65: 45E-51E.
- R59. Packer M. Diastolic function as a target of therapeutic interventions in chronic heart failure. *Eur Heart J* 1990; 11 (suppl C): 35-40.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R60. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. *Eur Heart J* 1990; 11 (suppl D): 44-52.
- R61. Packer M. Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. *Circulation* 1990; 82 (suppl I): 1-6.
- R62. Packer M. Pathophysiologic mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. *Circulation* 1990; 82 (suppl I): 77-88.
- R63. Massie BM, Packer M. Congestive heart failure: current controversies and future prospects. *Am J Cardiol* 1990; 66: 429-430.
- R64. Packer M. Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint. *Am J Cardiol* 1990; 66: 458-461.
- R65. Packer M. What causes tolerance to nitroglycerin? The 100-year-old mystery continues. *J Am Coll Cardiol* 1990; 16: 932-935.
- R66. Packer M. The placebo effect in heart failure. *Am Heart J* 1990; 120: 1579-1582.
- R67. Packer M. Calcium channel blockers in chronic heart failure: the risks of "physiologically rational" therapy. *Circulation* 1990; 82: 2254-2257.
- R68. Packer M, Kukin ML. Management of patients with heart failure and angina: Do co-existent diseases alter the response to cardiovascular drugs? *J Am Coll Cardiol* 1991; 17: 740-742.
- R69. Packer M. Hemodynamic consequences of anti-arrhythmic drug therapy in patients with chronic heart failure. *J Cardiovasc Electrophys* 1991; S240-S247.
- R70. Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. *Circulation* 1992; 85 (suppl I): 50-56.
- R71. Rouleau JL, Moye LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold M, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Delage F, Nadeau C, Lamas GA, Gottlieb SS, McCans J, Pfeffer M. Activation of neurohormonal systems following acute myocardial infarction. *Am J Cardiol* 1991; 68: 80D-86D.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R72. Pitt B, Cohn JN, Packer M, Pfeffer MA, Swedberg K. Determinants of survival and the effect of treatment on mortality in chronic congestive heart failure. *Clin Cardiol* 1992; 15: 323-329.
- R73. Packer M. Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms. *Am J Cardiol* 1992; 69: G150-G154.
- R74. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. *J Am Coll Cardiol* 1992; 20: 248-54.
- R75. Packer M. Pathophysiology of chronic heart failure. *Lancet* 1992; 340: 88-92.
- R76. Packer M. Treatment of chronic heart failure. *Lancet* 1992; 340: 92-95.
- R77. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. *Am J Cardiol* 1993; 71: 3C-11C.
- R78. Packer M. Calcium antagonists for congestive heart failure: evolving concepts in bridge building. *Cardiovasc Drug Ther* 1993; 7: 95-96.
- R79. Packer M. The search for the ideal positive inotropic agent. *N Engl J Med* 1993; 329: 201-202.
- R80. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990's: evolution of a major public health problem in cardiovascular medicine. *J Am Coll Cardiol* 1993; 22 (suppl): 3A-5A.
- R81. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray? *J Am Coll Cardiol* 1993; 22 (suppl): 119A-126A.
- R82. Lipicky R, Packer M. Role of surrogate endpoints in the evaluation of drugs for heart failure. *J Am Coll Cardiol* 1993; 22 (suppl): 179A-184A.
- R83. Packer M. The ischaemic heart: β -blockade or calcium channel blockade? *Eur Heart J* 1993; 14 (suppl F): 1.
- R84. Packer M. Use and abuse of clinical trials: Is the dose used the dose tested? *Cardiology* 1994; 85 (suppl 1): 2-6.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R85. Packer M. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. *Eur Heart J* 1995; 16 (suppl F): 4-6.
- R86. Williams JF Jr, Bristow MR, Fowler MB, Francis GS, Garson A Jr, Gersh BJ, Hammer DF, Hlatsky MA, Leier CV, Packer M, Pitt B, Ulliyot DJ, Wexler LF, Winters WL Jr. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). *Circulation* 1995; 92: 2764-2784.
- R87. Packer M. A novel approach to the development of positive inotropic agents for chronic heart failure. *J Cardiovasc Pharmacol* 1995; 26 (suppl 1): S52-S56.
- R88. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? *Circulation* 1995; 92: 1379-1382.
- R89. Packer M. Beta-blockade in the management of chronic heart failure: another step in the conceptual evolution of a neurohormonal model of the disease. *Eur Heart J* 1996; 17 (suppl B): 21-23.
- R90. Packer M. New concepts in the pathophysiology of heart failure: beneficial and deleterious interactions of endogenous haemodynamic and neurohormonal mechanisms. *J Intern Med* 1996; 239: 327-333.
- R91. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? *J Am Coll Cardiol* 1996; 28: 1323-1327.
- R92. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? *N Engl J Med* 1997; 336: 575-576.
- R93. Packer M. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. *Am J Cardiol* 1997; 80 (suppl 11A): 46L-54L.
- R94. Packer M. Beta-blockade in heart failure. Basic concepts and clinical results. *Am J Hypertension* 1998; 11: 23S-37S.
- R95. Packer M. Do beta-blockers prolong survival in chronic heart failure? a review of the experimental and clinical evidence. *Eur Heart J* 1998; 19 (suppl B): B40-B46.
- R96. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. *Prog Cardiovasc Dis* 1998; 48 (suppl): 39-52.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R97. Packer M, Cohn JN on behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. *Am J Cardiol* 1999; 83 (suppl 2A): 1A-38A.
- R98. Packer M, Miller AB. Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure? *Am J Cardiol* 1999; 84 (suppl 4A): 1L-2L.
- R99. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? *Eur J Heart Failure* 1999; 1: 41-45.
- R100. Packer M. Implications of the ATLAS study for clinical practice. *Int J Clin Pract Suppl* 1999;100: 21-3.
- R101. Packer M. Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. *Am Heart J* 2000;139: S202-6.
- R102. Packer M. Dispelling the myth: incorporating beta-blockers into practice guidelines. *Am J Manag Care* 2000; 6 (suppl): S313-6.
- R103. Packer M, Wittes J, Stump D. Terms of reference for Data and Safety Monitoring Committees. *Am Heart J* 2001; 141: 542-7.
- R104. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. *Am J Med* 2001; 110 (suppl 7A): 81-94.
- R105. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. *J Card Fail* 2001;7:176-82
- R106. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). *Circulation* 2001;104:2996-3007.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R107. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 2001;38:2101-13.
- R108. Deng MC, Smits JM, Packer M. Selecting patients for heart transplantation: which patients are too well for transplant? *Curr Opin Cardiol* 2002;17:137-44.
- R109. Packer M. The impossible task of developing a new treatment for heart failure. *J Cardiac Fail* 2002; 193-196.
- R110. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. *J Card Fail.* 2003:429-43.
- R111. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? *Circulation* 2003;107:656-8.
- R112. Konstam MA, Pina I, Lindenfeld J, Packer M. A device is not a drug. *J. Card Fail* 2003:155-7.
- R113. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? *Circulation* 2003;108:2950-3.
- R114. Konstam MA, Lindenfeld J, Pina IL, Packer M, Lazar RM, Warner Stevenson L; Heart Failure Society of America. Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America. *J Card Fail.* 2004;10:91-100.
- R115. Packer M. Milton Packer, MD, Director, Center for Biostatistics and Clinical Science at UT Southwestern. *J Investig Med.* 2004;52:421-4.
- R116. DeMets D, Califf R, Dixon D, Ellenberg S, Fleming T, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, Snapinn S, Stump D, Temple R, Whitley R. Issues in regulatory guidelines for data monitoring committees. *Clin Trials.* 2004;1:162-9.
- R117. Packer M. Controlled-release carvedilol: a concluding perspective. *Am J Cardiol* 2006;98(7A):67-9.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R118. Packer M. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. *Circ Heart Fail.* 2011;4:538-40.
- R119. Jessup M, Fox KA, Komajda M, McMurray JJ, Packer M. PARADIGM-HF--the experts' discussion. *N Engl J Med.* 2014;371:e15.
- R120. Levine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. *J Clin Invest.* 2015;125:14-24.
- R121. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating? *J Am Coll Cardiol.* 2015;65:1567-82.
- R122. Antman EM, Benjamin EJ, Harrington RA, Houser SR, Peterson ED, Bauman MA, Brown N, Bufalino V, Califf RM, Creager MA, Daugherty A, Demets DL, Dennis BP, Ebadollahi S, Jessup M, Lauer MS, Lo B, MacRae CA, McConnell MV, McCray AT, Mello MM, Mueller E, Newburger JW, Okun S, Packer M, Philippakis A, Ping P, Prasoon P, Roger VL, Singer S, Temple R, Turner MB, Vigilante K, Warner J, Wayte P for the American Heart Association Data Sharing Summit Attendees. Acquisition, analysis, and sharing of data in 2015 and beyond: a survey of the landscape: A conference report from the American Heart Association Data Summit 2015. *J Am Heart Assoc.* 2015;4. pii: e002810.
- R123. Packer M. Unbelievable folly of clinical trials in heart failure: the inconvenient truth about how investigators and guidelines weigh evidence. *Circ Heart Fail.* 2016 Apr;9(4). pii: e002837. doi: 10.1161/CIRCHEARTFAILURE.116.002837.
- R124. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. *Eur J Heart Fail.* 2016;18:482-9.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R125. Packer M. Love of angiotensin-converting enzyme inhibitors in the time of cholera. *JACC Heart Fail.* 2016 Apr 12. pii: S2213-1779(16)30045-2. doi: 10.1016/j.jchf.2016.02.012.
- R126. Nicholls M. Pioneers in cardiovascular medicine: Milton Packer MD. The Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center in Dallas, Texas, discusses his pioneering work in heart failure, a passion for rare books and the importance of upsetting the status quo. *Eur Heart J* 2016;37:1635-1637.
- R127. Packer M. Obituary. Farewell to Professor Henry Krum MD. A 'loving' tribute to Henry Krum by Milton Packer MD, friends since their first contact in 1992. *Eur Heart J* 2016;37:1633-1634.
- R128. Packer M. The room where it happens: a skeptic's analysis of the new heart failure guidelines. *J Card Fail.* 2016;22:726-30
- R129. Packer M. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. *Eur J Heart Fail.* 2016;18:1211-1219.
- R130. Packer M, Armstrong WM, Rothstein JM, Emmett M. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? *Ann Intern Med.* 2016;165:735-736.
- R131. Packer M. Heart failure's dark secret: does anyone really care about optimal medical therapy? *Circulation.* 2016;134:629-631.
- R132. Packer M. Data sharing: lessons from Copernicus and Kepler. *BMJ* 2016 Sep 14;354:i4911. doi: 10.1136/bmj.i4911.
- R133. Packer M. Angiotensin neprilysin inhibition for patients with heart failure. What if sacubitril/valsartan were a treatment for cancer? *JAMA Cardiol* 2016;1:971-972.
- R134. Packer M. Development and evolution of a hierarchical clinical composite endpoint for the evaluation of drugs and devices for acute and chronic heart failure: a 20-year perspective. *Circulation* 2016;134:1664-1678.
- R135. Packer M, McMurray JJV. Importance of endogenous vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. *Lancet.* 2016;389:1831-1840.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R136. Packer M. Cobalt cardiomyopathy: a critical reappraisal in light of a recent resurgence. *Circ Heart Fail*. 2016 Dec;9(12). pii: e003604.
- R137. Packer M. Double vision: replicating a trial showing a survival benefit. *JACC Heart Fail* 2017;5:232-235.
- R138. Packer M. Tetralogy of Fallow: four trials and tribulations. *JACC Heart Fail* 2017;5:408-410.
- R139. Packer M. Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial? *Eur J Heart Fail* 2017;19:779-781.
- R140. Packer M. Who should deliver medical therapy for patients with chronic heart failure? An immediate call for action to implement a community-based collaborative solution. *Circ Heart Fail* 2017 Aug;10(8). pii: e004332. doi: 10.1161/CIRCHEARTFAILURE.117.004332.
- R141. Packer M. Why has a run-in period been a design element in most landmark clinical trials? Analysis of the critical role of run-in periods in drug development. *J Card Fail*. 2017;23:697-699.
- R142. Packer M, Anker SD, Butler J, Filippatos G, M.D., Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of heart failure: proposal of a novel mechanism of action. *JAMA Cardiol* 2017;2:1025-1029.
- R143. Packer M. How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence. *Eur J Heart Fail*. 2017;19:1353-1354.
- R144. Packer M. The absence of an ideal observer: Why some clinical trials may not be what we think they are. *Circulation* 2017;136:1085-1086.
- R145. Packer M. Is the way to someone's heart through their stomach? The cardiorenal paradox of incretin-based hypoglycemic drugs in heart failure. *Circ Heart Fail* 2017 Oct;10(10). pii: e004551. doi: 10.1161/CIRCHEARTFAILURE.117.004551.
- R146. Packer M. Activation and inhibition of sodium-hydrogen exchange is a mechanism that links the pathophysiology and treatment of diabetes with that of heart failure. *Circulation* 2017;136:1548-1559.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R147. Packer M. Are meta-analyses a form of medical fake news? Thoughts about how they should contribute to medical science and practice. *Circulation* 2017;136:2097-2099.
- R148. Packer M. The imminent demise of cardiovascular drug development. *JAMA Cardiol* 2017;2:1293-1294.
- R149. Packer M. Heart failure with a mid-range ejection fraction: a disorder that a psychiatrist would love. *JACC Heart Fail* 2017;5:805-807.
- R150. Zannad F, de los Angeles Alonso Garcia M , Borer J, Stough WG, Clutton-Brock T , Rosenberg Y, Packer M. The role of payers in the development of cardiovascular therapeutics: misalignment between approval and reimbursement. *J Am Coll Cardiol* 2017;70:2822-2830.
- R151. Packer M. Absence of an ideal observer II: The agonizing search for experts without a conflict of interest. *Circulation* 2017;136:2400-2402.
- R152. Packer M. Why is the use of digitalis withering? Another reason that we need medical heart failure specialists. *Eur J Heart Fail* 2018;20:851-852
- R153. Packer M. Will long-acting glucagon-like peptide-1 analogs recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? *Eur J Heart Fail* 2018;20:973-977.
- R154. Packer M. Early worsening of renal function after treatment with antihyperglycemic drugs: a consistent but neglected finding in large-scale trials. *Am J Med* 2018;131:337-338.
- R155. Packer M. Acute heart failure is an event rather than a disease: a plea for a radical change in thinking and in therapeutic drug development. *JACC Heart Fail* 2018;6:73-75.
- R156. Packer M. Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. *Eur J Heart Fail* 2018;20:49-51.
- R157. Packer M. Heart failure: the most important, preventable and treatable cardiovascular complication of type 2 diabetes. *Diabetes Care* 2018;41:11-13.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R158. Packer M. CardioPulse: The future of the treatment of heart failure? Five imaginative predictions for the treatment of Heart Failure by 2028 are proposed by Milton Packer. *Eur Heart J* 2018;39:5-7.
- R159. Packer M. Role of sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. *Diab Obes Metab* 2018;20:800-811.
- R160. Packer M. Is the popularity of dipeptidyl peptidase-4 inhibitors in type 2 diabetes justified? Insights from mechanistic studies and clinical trials. *Am J Med* 2018; Jul;13:e287-e289.
- R161. Packer M. Should we be combining glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in treating diabetes? *Am J Med.* 2018;131:461-463.
- R162. Packer M. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. *Cardiovasc Diabetol* 2018 Jan 8;17(1):9. doi: 10.1186/s12933-017-0648-x.
- R163. Packer M. Derangements in adrenergic-adipokine signaling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. *Eur J Heart Fail.* 2018;20:873-878.
- R164. Packer M. Is metformin beneficial for heart failure in patients with type 2 diabetes? *Diabetes Res Clin Pract* 2018;136:168-170.
- R165. Packer M. Does neprilysin inhibition potentiate or minimize the adverse effects of glucagon-like peptide-1 receptor agonists in chronic heart failure? *J Card Fail* 2018;24:109-111.
- R166. Packer M. Have we really demonstrated the cardiovascular safety of antihyperglycemic drugs? Rethinking the meaning of macrovascular and microvascular disease in type 2 diabetes. *Diab Obes Metab* 2018;20:1089-1095.
- R167. Packer M. Data sharing in medical research: trust is the elephant in the room. *BMJ* 2018 Feb 14;360:k510. doi: 10.1136/bmj.k510.
- R168. Packer M. Do most obese people with exercise intolerance and a normal ejection fraction have treatable heart failure? *Am J Med* 2018;131:863-864.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R169. Packer M. Higher mortality rate in patients with heart failure who are taking antidiabetic medications and achieve recommended levels of glycemic control. *Diabetes Obes Metab.* 2018;20:1766-1769.
- R170. Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically-mediated cardiotoxicity? Clues from laboratory models and clinical trials. *Circ Res.* 2018;122:928-932.
- R171. Packer M. Do sodium-glucose cotransporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. *Diabetes Obes Metab.* 2018;20:1361-1366.
- R172. Packer M. Augmentation of glucagon-like peptide-1 receptor signaling by neprilysin inhibition: potential implications for patients with heart failure. *Eur J Heart Fail.* 2018;20:973-977.
- R173. Packer M. Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for sodium-glucose cotransporter 2 inhibitors. *Eur J Heart Fail* 2018;20:1100-1105.
- R174. Packer M. Contrasting effects on the risk of macrovascular and microvascular events of antidiabetic drugs that promote natriuresis and lower blood pressure. *Diabet Med.* 2018;35:707-713.
- R175. Packer M. The leptin-aldosterone-neprilysin axis: identification of its role in the pathogenesis of the three phenotypes of heart failure in obese people. *Circulation* 2018;137:1614-1631.
- R176. Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin and sodium-glucose cotransporter-2. *JACC Heart Fail* 2018;6:633-639.
- R177. Packer M. Worsening heart failure during the use of dipeptidyl peptidase-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. *JACC Heart Fail.* 2018;6:445-451.
- R178. Packer M. Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. *Int J Cardiol.* 2018;261:130-133.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R179. Packer M. Epicardial adipose tissue: the transducer that mediates the effects of systemic inflammation on the myocardium. *J Am Coll Cardiol* 2018;71:2360-2372.
- R180. Packer M. Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. *J Diabetes Complications*. 2018;32:616-617.
- R181. Packer M. The alchemist's nightmare: might mesenchymal stem cells that are recruited to repair the injured heart be transformed into fibroblasts rather than cardiomyocytes? *Circulation*. 2018;137:2068-2073.
- R182. Packer M. Does a target dose or a target heart rate matter to outcomes when prescribing beta-blockers to patients with chronic heart failure? *Circ Cardiovasc Qual Outcomes* 2018 Apr;11(4):e004605. doi: 10.1161/CIRCOUTCOMES.118.004605.
- R183. Packer M. Potentiation of insulin signaling contributes to heart failure in type 2 diabetes? A hypothesis supported by both mechanistic studies and clinical trials. *JACC Basic Transl Sci* 2018;3:415-419.
- R184. Packer M, Kowey PR. Building castles in the sky: catheter ablation for patients with atrial fibrillation and chronic heart failure. *Circulation*. 2018;138:751-753.
- R185. Packer M. Questioning the obvious: does dyspnea really matter in heart failure? *Eur Heart J* 2018;39:2822-2824.
- R186. Packer M. The CABANA Trial: an honourable view. *Eur Heart J*. 2018 Aug 7;39(30):2770. doi: 10.1093/eurheartj/ehy381.
- R187. Packer M. The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction. *Eur J Heart Fail*. 2018;20:1567-1569.
- R188. Packer M. Obesity-associated heart failure as a theoretical target for treatment with mineralocorticoid receptor antagonists. *JAMA Cardiol*. 2018;3:883-887.
- R189. Packer M, Pitt B. Future large-scale clinical trials in cardiovascular medicine: challenges and uncertainties. *Eur J Heart Fail* 2018;20:1645-1648.
- R190. Packer M. The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. *Eur J Heart Fail* 2018;21:156-162.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R191. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. *JACC Cardiovasc Imaging* 2019;12:353-362.
- R192. Packer M. When cardiovascular trials collide: a novel framework emerges from the dissonance created by the MITRA-FR and COAPT trials. *Eur Heart J* 2019;40:501-504.
- R193. Packer M. Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. *Eur J Heart Fail* 2019;21:398-401.
- R194. Packer M. Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction. *Eur J Heart Fail* 2019; Apr 24. doi: 10.1002/ejhf.1469.
- R195. Packer M. What have we learned from randomized controlled trials of catheter ablation for atrial fibrillation in patients with chronic heart failure? *Circ Arrhythm Electrophysiol.* 2019 Apr;12(4):e007222. doi: 10.1161/CIRCEP.119.007222
- R196. Packer M. Is any patient with chronic heart failure receiving the right dose of the right beta-blocker in primary care? *Am J Med.* 2019 Apr 12. pii: S0002-9343(19)30311-0. doi: 10.1016/j.amjmed.2019.03.026.
- R197. Grayburn PA, Stone GW, Mack MJ, Packer M. Defining secondary mitral regurgitation: evidence that the 2017 updated guidelines got it right. *Structural Heart* 2019;3:284-287.
- R198. Packer M. Neurohormonal and transcatheter repair strategies for proportionate and disproportionate functional mitral regurgitation in heart failure. *JACC Heart Fail.* 2019;7:518-521.
- R199. Packer M. Contrasting effects of pharmacological, procedural and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart failure. *Circulation.* 2019;140:779-789.
- R200. Packer M. Reconceptualization of the molecular mechanism by which SGLT2 inhibitors reduce the risk of heart failure events. *Circulation* 2019;140:443-445.

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R201. Packer M. Exacerbation of pre-existing abnormalities of left atrial systolic, diastolic and neurohormonal functions following catheter ablation for atrial fibrillation. *Eur Heart J*. 2019;40:1873-1879.
- R202. Packer M. Is atrial fibrillation a biomarker of or contributor to the disease process in patients with chronic heart failure? *Am J Med* 2019 Jun 17. pii: S0002-9343(19)30464-4. doi: 10.1016/j.amjmed.2019.05.026.
- R203. Packer M. Compelling first-line alternatives to an implantable cardioverter-defibrillator for the prevention of sudden death in patients with chronic heart failure. *Circ Arrhythm Electrophys* 2019 Jun;12(6):e007430. doi: 10.1161/CIRCEP.119.007430.
- R204. Packer M. Why are physicians so confused about acute heart failure? *N Engl J Med* 2019;381:776-777.
- R205. Packer M. Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey. *Eur Heart J* 2019 May 23. pii: ehz281. doi: 10.1093/eurheartj/ehz281.
- R206. Packer M. Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favorably affect ventricular structure. *Eur J Heart Fail*. 2019;21:823-826.
- R207. Packer M. The parable of Schrödinger's cat and the illusion of statistical significance in clinical trials. *Circulation*. 2019;140:799-800.
- R208. Packer M. Risks of intensive treatment of long-standing atrial fibrillation in patients with chronic heart failure with a reduced or preserved ejection fraction. *Circ Qual Outcomes* 2019 Aug;12(8):e005747. doi: 10.1161/CIRCOUTCOMES.119.005747
- R209. Packer M. Critical role of the epicardium in mediating cardiac inflammation and fibrosis in patients with type 2 diabetes. *Diabetes Obes Metab* 2019;21:1765-1768.
- R210. Packer M. Nonarrhythmic sudden cardiac death in chronic heart failure: a preventable event? *JAMA Cardiol*. 2019 Jul 17. doi: 10.1001/jamacardio.2019.2228. [Epub ahead of print]

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R211. Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? *Eur Heart J*. 2019 Aug 7. pii: ehz553. doi: 10.1093/eurheartj/ehz553. [Epub ahead of print]
- R212. Packer M. Neurohormonal antagonists should be preferred to an implantable cardioverter-defibrillator for the prevention of sudden death in chronic heart failure. *JACC Heart Fail* 2019 Sep 7. pii: S2213-1779(19)30405-6. doi: 10.1016/j.jchf.2019.05.013. [Epub ahead of print]
- R213. Butler J, Packer M, Greene SJ, Fiuzat M, Anker S, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CM. Heart failure endpoints in cardiovascular outcome trials of patients with type 2 diabetes: A critical evaluation of clinical and regulatory issues. *Circulation* (in press)
- R214. Packer M, Lam CSP, Jund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. *Circulation* (in press)
- R215. Packer M. Epicardial adipose tissue inflammation can cause the distinctive pattern of cardiovascular disorders seen in psoriasis. *Am J Med* 2019 Sep 11. pii: S0002-9343(19)30750-8. doi: 10.1016/j.amjmed.2019.08.027. [Epub ahead of print]
- R216. Packer M. Do drugs that ameliorate epicardial adipose tissue inflammation have concordant benefits on atrial fibrillation and on heart failure with a preserved ejection fraction, but not in heart failure with a reduced ejection fraction? *J Card Fail* (in press)
- R217. Packer M. Heart failure with a preserved ejection fraction is the substrate for stroke in obesity and diabetes independent of atrial fibrillation. *JACC Heart Fail* (in press)
- R218. Packer M. Do most patients with obesity or type 2 diabetes who have atrial fibrillation have undiagnosed heart failure? Implications for understanding mechanisms and improving diagnosis and treatment. *Eur J Heart Fail* (in press)
- R219. Butler J, Anker SD, Packer M. Redefining heart failure with reduced ejection fraction. *JAMA* 2019 Sep 13. doi: 10.1001/jama.2019.15600. [Epub ahead of print]

Milton Packer, M.D.

REVIEWS, EDITORIALS AND COMMENTARIES [PEER-REVIEWED] (CONTINUED)

- R220. Packer M. A compelling case for less aggressive arrhythmia management in patients with chronic heart failure and long-standing atrial fibrillation. *J Card Fail* (in press)
- R221. Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. *Cardiovasc Diabetol* (in press)
- R222. Packer M. Heightened risk of intensive rate-control in patients with atrial fibrillation who are obese or have type 2 diabetes: A critical review and re-evaluation

Milton Packer, M.D.

SYMPOSIUM EDITORSHIPS

- S1. Packer M, Frishman W, eds. Verapamil therapy for stable and unstable angina pectoris. *Am J Cardiol* 1982; 50: 881-928; 1153-1195.
- S2. Packer M, ed. Physiologic determinants of survival in patients with congestive heart failure. *Circulation* 1987; 75 (suppl IV): 1-111.
- S3. Packer M, ed. Therapeutic challenges in the management of congestive heart failure. *J Am Coll Cardiol* 1988; 12: 262-283 and 546-569.
- S4. Packer M, ed. Advances in the pathogenesis and treatment of heart failure. *Curr Opinion Cardiol* 1989; 4: 339-376.
- S5. Packer M, ed. Hormone-electrolyte interactions in congestive heart failure. *Am J Cardiol* 1990; 65: 1E-52E.
- S6. Packer M, ed. Role of the sympathetic nervous system in heart failure: basic mechanisms and clinical directions. *Circulation* 1990; 82 (suppl I): 1-113.
- S7. Massie BM, Packer M, eds. Congestive heart failure: current controversies and future prospects. *Am J Cardiol* 1990; 66: 429-471.
- S8. Packer M, Pouleur H, eds. The ischaemic heart — β -blockade or calcium channel blockade? *Eur Heart J* 1993; 14 (suppl F): 1-34.
- S9. Garg R, Packer M, Pitt B, Yusuf S, ed. Mechanisms and management of heart failure: implications of clinical trials for clinical practice. *J Am Coll Cardiol* 1993; 22 (suppl): 1A-224A.
- S10. Packer M, Cohn JN on behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. *Am J Cardiol* 1999; 83 (suppl 2A): 1A-38A.
- S11. Miller AB, Packer M, eds. Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure? *Am J Cardiol* 1999; 84 (suppl 4A): 1L-33L.

Milton Packer, M.D.

BOOKS

- B1. Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, Connecticut: Appleton-Century-Crofts, 1984.
- B2. Willerson JT, Baim DS, Packer M, Zipes DL, eds. Cardiovascular Therapy. New York, New York: Gower Medical Publishing, 1993.

FOREWARDS IN BOOKS

- F1. Packer M. In: Leier CV, Boudoulas H. CardioRenal Disorders and Diseases. 2nd edition. Mount Kisco: Futura, 1992; iii-vi.

CHAPTERS IN BOOKS

- C1. Packer M, Medina N, Yushak M. Effets hemodynamiques de l'association verapamil beta-bloquers dans l'angor de repos. In: Bricaud H, Bertrand M, Delahaye J-P, eds. Symposium international sur la place des calcium-bloquers dans le traitement des affections coronariennes et de l'hypertension arterielle. Amsterdam: Excerpta Medica, 1983; 372-384.
- C2. Packer M, Frishman WH. Calcium channel antagonists in perspective. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; xvii-xxxi.
- C3. Singh BN, Chew CYC, Josephson MA, Packer M. Hemodynamic mechanisms underlying the antianginal actions of verapamil. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 23-40.
- C4. Frishman WH, Klein NA, Klein P, Strom JA, Strair R, Kirschen N, Le Jemtel TH, Pollack S, Sonnenblick EH, Packer M. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton Century-Crofts, 1984; 107-128.
- C5. Packer M, Leon MB, Bonow RO, Kieval J, Rosing DR, Bala Subramanian V. Hemodynamic and clinical effects of combined therapy with verapamil and propranolol in ischemic heart disease. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 143-165.
- C6. Packer M, Frishman WH, Packer M, Mehta J, Parodi O, Bala Subramanian V. Long-term effectiveness of verapamil in stable and unstable angina pectoris. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 183-197.

Milton Packer, M.D.

CHAPTERS IN BOOKS (CONTINUED)

- C7. Frishman WH, Kirsten EB, Klein MD, Pine MB, Johnson SM, Hillis LD, Packer M, Kates R. Clinical relevance of verapamil plasma levels in stable angina pectoris. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 199-210.
- C8. Frishman WH, Klein NA, Strom JA, Shamooh H, Willens H, Klein P, Kirschen N, Iosrio L, Le Jemtel TH, Pollack S, Sonnenblick EH, Packer M. Comparative effects of abrupt withdrawal of verapamil and propranolol in angina pectoris. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 211-222.
- C9. Klein HO, Packer M, Kaplinsky E. Comparative effectiveness of verapamil and digoxin in atrial fibrillation. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century Crofts, 1984; 269-288.
- C10. Frishman WH, Ocken S, Spivack C, Charlap S, Packer M. Calcium channel blocking drugs in the treatment of systemic hypertension. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 291-312.
- C11. Rosing DR, Bonow RO, Packer M, Epstein SE. Verapamil therapy for the management of hypertrophic cardiomyopathy. In: Packer M, Frishman WH, eds. Calcium Channel Antagonists in Cardiovascular Disease. Norwalk, CT: Appleton-Century-Crofts, 1984; 313-339.
- C12. Packer M. Interaction of the renin-angiotensin system and survival in congestive heart failure. In: Nicholls MG, ed. New Concepts in Cardiovascular Medicine. Auckland: Adis Press Limited, 1986; 69-75.
- C13. Packer M. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. In: Rappaport E, ed. Cardiology Update Reviews for Physicians 1986. New York: Elsevier Science Publishing Co., Inc., 1986; 124-143.
- C14. Packer M. Chronic congestive heart failure. In: Balyess TM, Brain MC, Cherniak RM, eds. Current Therapy in Internal Medicine - 2. Burlington, Ontario: B. C. Decker, Inc., 1987; 964-967.
- C15. Packer M. Chronic congestive heart failure. In: Fortuin N, ed. Current Therapy in Cardiovascular Disease - 2. Burlington, Ontario: B. C. Decker Inc., 1987; 165-169.

Milton Packer, M.D.

CHAPTERS IN BOOKS (CONTINUED)

- C16. Packer M. Utility of prazosin in the management of patients with severe chronic congestive heart failure. In: Bussman W-D, Just H, eds. *Vasoaktive Substanzen bei Herzinsuffizienz*. Heidelberg: Springer-Verlag, 1987; 125-127.
- C17. Packer M. Converting-enzyme inhibition in the management of patients with severe chronic congestive heart failure. In: Bussman W-D, Just H, eds. *Vasoaktive Substanzen bei Herzinsuffizienz*. Heidelberg: Springer-Verlag, 1987; 219-223.
- C18. Packer M. Adverse hemodynamic and clinical responses to long-term inotropic therapy in patients with severe chronic congestive heart failure. In: Bussman W-D, Just H, eds. *Vasoaktive Substanzen bei Herzinsuffizienz*. Heidelberg: Springer-Verlag, 1987; 331-333.
- C19. Packer M. Are placebo-controlled trials necessary in the evaluation of new therapeutic agents in severe chronic heart failure? In: Morganroth J, Moore EN, eds. *Congestive Heart Failure*. Norwell, Massachusetts: Martinus Nijhoff Publishing, 1987; 143-149.
- C20. Packer M. Treatment strategies in the management of patients with primary pulmonary hypertension. In: Konstam MA, Isner JM, eds. *The Right Ventricle*. Norwell, Massachusetts: Kluwer Academic Publishers, 1988; 209-223.
- C21. Packer M. Survival in patients with chronic congestive heart failure and its potential modification by drug therapy. In Cohn J, ed. *Drug Treatment for Heart Failure*. Secaucus, New Jersey: Advanced Therapeutics Communications, 1988; 261-292.
- C22. Packer M. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. In: Armstrong PW, ed. *Congestive Heart Failure: New Choices Afford New Approaches*. Toronto: The Medicine Publishing Foundation, 1988; 43-61.
- C23. Packer M. Pitfalls in the design and evaluation of clinical trials of intravenously administered cardiovascular drugs. In: Morganroth J, Moore EN, eds. *Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic and Hypolipidemic Agents*. Norwell, Massachusetts: Kluwer Academic Publishers, 1989; 15-22.
- C24. Packer M. Management of persistent heart failure following an acute myocardial infarction. In: *Modern Coronary Care*. Francis GS, Alpert JS, eds. Little, Brown and Co., Boston, Massachusetts, 1990; 573-583.

Milton Packer, M.D.

CHAPTERS IN BOOKS (CONTINUED)

- C25. Packer M. How to demonstrate the efficacy of a new drug for the treatment of chronic heart failure. In: Morganroth J, Moore EN, eds. Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Norwell, MA: Kluwer Academic Publ, 1990: 167-75.
- C26. Packer M. Angiotensin converting-enzyme inhibitors in chronic heart failure. In: Cardiovascular Drug Therapy. Messerli FA, ed. W. B. Saunders Company, Philadelphia, Pennsylvania, 1990; 761-769.
- C27. Packer M. Management of congestive heart failure. In: Willerson JT, Packer M, Zipes D, eds. Cardiovascular Drug Therapy. Gower Medical Publishing, New York, New York, 1992; 2.1-2.87.
- C28. Packer M. Nonadrenergic neurohormonal alterations in congestive heart failure. In: Greenberg B, Hosensput J. Congestive Heart Failure: Mechanisms and Management. (in press)
- C29. Packer M. Drugs for heart failure that interfere with the renin-angiotensin system. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee, Coats AJS. Heart Failure. Churchill Livingstone, New York, New York, 1997; 687-700.
- C30. Packer M. Management of heart failure. Cecil Textbook of Medicine (21st Edition). Goldman L, Bennett JC, eds. St. Louis: WB Saunders Co., 2000; 216-227.
- C31. Packer M. Management of heart failure. Cecil Textbook of Medicine (22st Edition). Goldman L, Bennett JC, eds. St. Louis: WB Saunders Co., 2003 (in press).